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 Background: The possibility of an association between the use of protease 
inhibitors (PI) by HIV/AIDS patients and the occurrence of T2DM mellitus (T2DM) is 
largely debated. Medicare recipients are disproportionally affected by T2DM. 
Unfortunately, evidence is unavailable from that particular segment of the population. 
Clinical management of HIV/AIDS is progressively expanding to include 
chronic/metabolic complications, which may pose a significant economic burden to both 
the patients and the Medicare system, which are disproportionally impacted. 
Objectives: The aims of this project were to (1) examine the association between the use 
of PIs and the odds of developing T2DM among Medicare beneficiaries with HIV/AIDS, 
(2) assess any racial/ethnic disparity in odds of developing T2DM among Medicare 
beneficiaries with HIV/AIDS and (3) to determine the economic burden of comorbid 
T2DM among Medicare beneficiaries with HIV/AIDS. 
Methods: This study used a nationwide Medicare claims data from 2013 to 2017 to 
analyze a sample of Medicare beneficiaries diagnosed with HIV/AIDS based on the 
International Classification of Diseases, Ninth & Tenth Revision, Clinical Modification 
(ICD-9/10-CM) codes. In study aim 1 and 2, a nested case-control study design was used 
to analyze the odds of developing T2DM among beneficiaries with HIV/AIDS. 
HIV/AIDS positive beneficiaries enrolled continuously in Medicare Part A and Part B 
were included as well as those who never enrolled in a Health Maintenance Organization 
 
vi 
(HMO) and those without a previous history of T2DM. A T2DM diagnosis was 
determined using T2DM specific ICD-9/10-CM codes. Two matched therapy group pairs 
– (PI versus non-PIs, PI versus no-ART) were generated using a 1:1 greedy Propensity 
Score (PS) matching procedure. Multivariate logistic regressions were performed to 
assess the odds of developing T2DM in both groups and for each race sub-group.  
In study aim 3, a pooled cross-sectional study design was used to determine the 
economic burden of comorbidity T2DM in beneficiaries with HIV/AIDS. The analytical 
sample consists of HIV/AIDS positive beneficiaries enrolled continuously in Part A/B 
and never enrolled in an HMO. We assessed records of T2DM diagnosis using T2DM 
specific ICD-9/10-CM codes. Total medical costs, total prescription costs, total inpatient 
costs, total outpatient costs, total out of pocket (OOP) and total Medicare costs were 
assessed from Medicare claims and prescription drug files. Generalized linear models 
with a log-link and a gamma distribution were used to examine the impact of comorbid 
T2DM on different costs. All costs were adjusted to the 2017-dollar value using the 
medical component of a consumer price index based on Medical Expenditure Panel 
Survey (MEPS) guidelines. 
Results: In study aims 1 and 2, the analytical sample consists of 2,353 beneficiaries with 
HIV/AIDS which includes 342 beneficiaries with T2DM, 2011 beneficiaries without 
T2DM, 1005 beneficiaries treated with PIs, 766 beneficiaries treated with non-PIs and 
582 beneficiaries who had no-ART. Exactly 484 matched beneficiaries per therapy group 
was generated for PI versus non-PI pair and 490 beneficiaries per therapy group for the 
PI versus no-ART pair. Matched beneficiaries in the PI versus non-PI therapy group are 
mostly older 55 years and above per group, mostly male beneficiaries – 77.1% (n=373) 
vii 
and consists mainly of  Caucasians – 49% (n=237) and African Americans -45% (n=218) 
per group. Matched beneficiaries in the PI versus no-ART therapy group are mostly older 
than 55 years and above per group, mostly male beneficiaries – 75.9% (n=372) per group 
and consists mainly of  Caucasians – 42.7 % (n=209) and African Americans -50% 
(n=245) per group. After adjusting for covariates: (1) in the PI versus non-PI pair: the 
odds of a T2DM diagnosis was higher among PI-users: AOR= AOR=1.76 [95% CI: 1.17-
2.64], Caucasian PI-users: AOR=1.81 [95% CI: 1.02-3.22] and African-American PI-
users: AOR= 1.86 [95% CI: 1.03-3.36] compared to non-PI users on average, and (2) in 
the PI versus no-ART pair: the odds of a T2DM diagnosis was higher among PI users 
AOR=1.87 [95% CI: 1.25-2.81], Caucasian PI-users: AOR=1.96 [95% CI: 1.14- 3.39] 
and African-American PI-users: AOR=2.05 [95% CI: 1.03-4.09] compared to ART naïve 
beneficiaries on average.  
In study aim 3, a total of 2,509 eligible beneficiaries were identified of which 19.9 
% (n=498) had T2DM and 80.2% (n=2,011) are non-T2DM beneficiaries. Beneficiaries 
with comorbid T2DM had a higher total prescription cost than non-T2DM beneficiaries 
across all costs: (mean total medical: T2DM beneficiaries ($189,543) versus non-T2DM 
beneficiaries ($124,052), P= <.0001). After adjusting for covariates, compared to 
beneficiaries without comorbid T2DM, beneficiaries with comorbid T2DM had higher: 
total hospitalization cost: 63.34% (95% CI: 42.73% -86.94 %), total outpatient cost: 
50.26% (95% CI: 30.70%-72.75%), total OOP cost: 59.15% (95% CI: 40.02%-80.92%), 
total Medicare cost: 27.95% (95% CI: 13.81%-43.84%) and total medical cost: 27.83% 
(95% CI: 14.27%-43.00%), compare to non-T2DM beneficiaries, on average. 
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Conclusion: Use of PIs is associated with a higher odd of T2DM diagnosis. 
Results are consistent within African Americans and Caucasian race-sub-groups; 
however, odds were higher among African Americans beneficiaries than Caucasians. 
Comorbid T2DM may impose a significant economic burden on Medicare beneficiaries 
with HIV/AIDS. The findings of this study suggest evidence-based risk management 
approach in the clinical use of PIs to avoid HIV treatment-related T2DM among 
Medicare population, who are already enormously predisposed as well as personalized 
risk management approach in the context of racial variation in treatment-related T2DM. 
The findings of this study could be helpful to the Medicare they seek to address concerns 
about its future financial solvency amidst a growing aging population and increasing per 
capita costs. Evidence of total OOP costs benefit the Medicare as they seek to reduce 
drug costs to benefit HIV positive beneficiaries who face high OOP cost.
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Anti-retroviral Therapies (ARTs) are very effective in viral suppression and 
immune system maintenance given that they act on different viral targets thereby ensuring 
a reduction in HIV-related mortality rates. However, the safety and tolerability of ARTs 
have been largely controversial. Butt and colleagues reported an increased risk of diabetes 
among veterans infected with HIV 1. A multicenter study shows that HIV-infected patients 
receiving Highly Active Anti-retroviral Therapy (HAART) are more than 4 times as likely 
to have an increased rate of diabetes than HIV-negative participants2. Contrary to these 
studies, Dimala et al. recently conducted a study to compare the diabetes risk score in 
HIV/AIDS patients on HAART and HAART-naïve patients. Their findings showed no 
statistically significant association between HAART and diabetes 3.  
In addition to the on-going debate, evidence on the Medicare population is 
unavailable because the focus of previous studies has been on other population rather than 
the Medicare population, in whom the risk of diabetes is most prominent. Contrary to the 
public perception that HIV is an infection that mainly affects young adults, recent studies 
have revealed that the HIV epidemiology in individuals aged 65 and older has been 
changing and worsening dramatically in the past decades and this population constitutes 





Racial disparities in access to HIV medications are an important determinant of 
racial variations in treatment outcomes and adverse medication related events. Racial 
disparities in receipt of HAART have been reported in previous studies 5. This was found 
to be true among Medicaid beneficiaries, which are expected to have equitable access to 
care given that Medicaid is structured to provide equal access to healthcare for all eligible 
enrollees. Racial disparity in access to care among patients enrolled in Medicaid may 
suggest a potential disparity in treatment related adverse events not only among the 
Medicaid population, but also among the Medicare population.   
HIV infection, ART use, and age are important predisposing factors to metabolic 
syndromes such as diabetic comorbidity in HIV/AIDS. Comorbid diabetes in HIV patients 
is most likely to occur as treated patients grow older.6 These comorbidities may pose 
significant clinical challenges as well as an economic burden for the US Medicare system 
given the increasing number of surviving younger patients who will become eligible for 
Medicare in the nearest decade.7 
1.1     Human Immunodeficiency Virus (HIV) 
HIV is the virus that attacks the human T-cells, specifically the CD4 cells ,which 
protect the body from infection and other related foreign bodies.8 The HIV infection 
destroys the CD4 cells of the human hosts, thereby making the host’s immune system 
weak or unable to fight against infections.8 Thus, the human host ultimately becomes 
more vulnerable to opportunistic infections.8 This can cause symptoms that signal 






HIV is classified into HIV-1 and HIV-2 ,which are different and can both result in 
AIDS.9 HIV-1 is the most common and most prevalent type of HIV globally. HIV-2 is 
less common and occurs in a much smaller number of people mostly from the West 
African regions.9 In the US, patients infected with HIV-2 constitute only about 0.01% of 
all HIV cases.9 It is harder to transmit HIV-2 between humans and it also takes a longer 
time for AIDS symptoms to manifest. HIV is spread through contact and exchange of 
certain bodily fluids with an infected person. Fluid contact or exchange mainly occurs 
during unprotected sexual contact or sharing of injection needles during medical 
treatment, blood transfusions, or drug abuse. It can also be transferred from an infected 
mother to her child through the placenta and breast milk.8  
HIV infected person may experience any type of symptoms possible since the 
infection targets and impairs the immune system. Common symptoms that have been 
reported include fever and fatigue, sore mouth and throat, muscular aching, candida 
infection of the mouth, constant diarrhea, swollen lymph glands, seborrheic dermatitis 
and vaginal yeast infection.8 To detect the HIV infection, two major laboratory tests 
which involve a series of blood screenings may be conducted.9 Typically, the first test to 
be ordered by healthcare providers is the Enzyme Immunoassay (EIA), also referred to as 
the Enzyme-Linked Immunosorbent Assay (ELISA). ELISA detects HIV antibodies and 
antigens in the blood. It is recommended for individuals who have been exposed to HIV 
or those at high risk of contracting HIV.9 Following a positive ELISA test is the 
confirmation of HIV infection which is performed using the HIV differentiation assay.9 
Two main laboratory indices may be used to monitor treatment progress in an HIV 





less than 500 count/ml indicates immune suppression while a high-level of HIV RNA 
viral loads indicates severe infection.9  
1.2       Acquired Immunodeficiency Syndrome (AIDS) 
AIDS represents the terminal stage of the HIV infection during which patients 
experience severe damage to the immune system and a resultant presence of numerous 
opportunistic infections in the host’s system.10 According to the Centers for Disease 
Control (CDC), AIDS begins when HIV infected patients present with a CD4 cell count 
less than 200 count/ml.10 At this point the HIV/AIDS patients could experience illnesses 
such as pneumocystis carinii pneumonia, candida esophagitis, cryptococcal meningitis, 
AIDS dementia, toxoplasmosis encephalitis, progressive multifocal leukoencephalopathy, 
wasting syndrome, mycobacterium avium and cytomegalovirus infection.10 Currently, 
HIV/AIDS has no cure. However, available treatments do delay the progression of the 
disease, improves quality of life10, and increases life expectancy of HIV/AIDS patients to 
70 years.11  
1.3     HIV/AIDS in The United States  
 
In the United States (US), approximately 1.1 million people are living with 
HIV/AIDS, with approximately 37,600 new infections reported annually.12 Although the 
importance of prevention and treatment has been met with huge government efforts, 1 in 
7 of those infected are not aware that they have HIV virus.13 Over 700,000 people have 
died of HIV/AIDS related illnesses since the HIV epidemic began in the US in 1980s.12 
Although the size of the epidemic is small, relative to the entire US population,12 it has 





Southern region, in particular, is home to over 45% of US citizens currently living with 
HIV/AIDS, and accounts for about 50% of all new infections.12,14  
The HIV epidemic disproportionately impacts racial minorities, compared to the 
Caucasian majority.12 The majority of new HIV/AIDS infections occur among African 
Americans and Hispanics.12,15 Out of 1.1 million people living with HIV in the US, 
468,800 are African American; accounting for more people living with HIV than other 
ethnic groups.13 Furthermore, survival after an HIV diagnosis is lower in African 
Americans than among other racial groups. African Americans accounted for more than 
50 % of HIV/AIDS related deaths in 2016.12 
1.4 HIV/AIDS Treatment and Medications  
Antiretroviral therapy (ART) represents different classes of medicines used in the 
treatment of HIV/AIDS. Eight classes of ARTs have been approved by the Food and 
Drug Administration (FDA) and most of the member classes are currently in use.16,17 The 
primary therapeutic goal of ART use is to achieve maximum and stable viral load 
suppression, restore and sustain the immune system and its functions, improve quality of 
life, and reduce HIV-related morbidity and deaths.17 As shown in table 1.1, FDA 
approved classes of ARTs include: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), 
integrase strand-transfer inhibitors, fusion inhibitors, post attachment inhibitors, 







1.4.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)  
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are effective against HIV-1 
and HIV-218 and act by interrupting HIV replication through competitive inhibition of the 
HIV reverse transcriptase enzyme disrupting the HIV DNA chain.19 The reverse 
transcriptase enzyme is a specific DNA polymerase that enables transcription of the HIV 
RNA into a double-strand pro-viral DNA. This DNA, upon elongation, is incorporated 
into the host-cell genome through the addition of purine and pyrimidine nucleosides.19 
The NRTIs are structurally identical to the purine and pyrimidine nucleosides and are 
therefore incorporated into the pro-viral DNA chain, resulting in disruption of pro-viral 
DNA formation.19  NRTI was among the first of the ARTs to be approved for treatment 
of HIV/AIDS and they remain an integral component of the current standard treatment 
guidelines. The FDA approved seven classes of NRTIs which are currently in use  
including: abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and 
zidovudine.20 Several adverse effects reported with the use of NRTIs include: lactic 











Table 1.1 List of FDA approved single ART class 






Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Ziagen Abacavir sulfate ABC December 17, 
1998 
Emtriva Emtricitabine FTC July 2, 2003 
Epivir Lamivudine 3TC November 17, 
1995 
Viread Tenofovir disoproxil 
fumarate 
TDF (Tenofovir DF) October 26, 2001 
Retrovir zidovudine AZT, ZDV 
(Azidothymidine)  
March 19, 1987 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Pifeltro Doravirine DOR August 30, 2018 
Sustiva Efavirenz EFV September 17, 
1998 
Intelence Etravirine ETR January 18, 2008 
Viramune Nevirapine  NVP June 21, 1996 
Viramune 
XR  
 Extended release 
Nevirapine 
 March 25, 2011 
Edurant Rilpivirine RPV (rilpivirine 
hydrochloride) 
May 20, 2011 
Protease Inhibitors (PIs) 
Reyataz Atazanavir ATV (atazanavir 
sulfate,) 
June 20, 2003 
Prezista Darunavir DRV (darunavir 
ethanolate) 
June 23, 2006 
Lexiva Fosamprenavir FOS-APV, FPV 
(fosamprenavir 
calcium) 
October 20, 2003 
Norvir Ritonavir RTV March 1, 1996 
Invirase Saquinavir SQV (Saquinavir 
mesylate) 
December 6, 1995 
Aptivus Tipranavir TPV June 22, 2005 
Fusion Inhibitors 
Fuzeon Enfuvirtide T-20 March 13, 2003 
CCR5 Antagonists 
Selzentry Maraviroc MVC August 6, 2007 
Integrase Inhibitors 
Tivicay Dolutegravir DTG, (Dolutegravir 
sodium) 





Isentress Raltegravir RAL (Raltegravir 
potassium) 
October 12, 200 
Isentress 
HD 
  May 26, 2017 
Post-Attachment Inhibitors 
Trogarzo ibalizumab-uiyk Hu5A8, IBA, 
Ibalizumab, TMB-
355, TNX-355 
March 6, 2018 
Pharmacokinetic Enhancers 
Tybost cobicistat COBI, C September 24, 
2014 
 
1.4.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are a class of ART 
that act by non-competitively binding on the p66 subunit at a hydrophobic pocket distant 
of HIV reverse transcriptase enzyme, thereby altering the active site and limiting viral 
activities.21 All NNRTI classes of ART exhibit similar mechanisms of action. Members 
of  the NNRTI class include nevirapine, delavirdine, etravirine, rilpivirine, and 
efavirenz.20 All member classes are effective against HIV-1 with etravirine having an 
additional activity against HIV-2.22 One commonly reported adverse event of NNRTIs is 
a rash, which manifests within the first few weeks of therapy and resolves as therapy 
continues.20 Other adverse events include hepatotoxicity, insomnia, vivid dreaming, 
dizziness, hallucinations, and confusion.20 
1.4.3 Protease Inhibitors (PIs) 
Protease Inhibitors (PIs) are a class of ARTs which act by competitively 
inhibiting the HIV protease enzyme responsible for the maturation of viral cells late in 
the viral cycle. The HIV protease enzyme facilitates the maturation of viral cells and 





subsequent cleavage of polypeptides and viral cell maturation. 23 They are effective 
against HIV-1 and HIV-2 clinical isolates.23 Members of the PI class include ritonavir, 
atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, saquinavir, amprenavir, 
lopinavir/ritonavir, and tipranavir.   
1.4.4 Integrase Strand-Transfer Inhibitors (INSTIs) 
Integrase Strand-Transfer Inhibitors (INSTIs) are known for their ability to 
competitively bind metallic ions in viral active sites to prevent the covalent linkage of 
pro-viral DNA to the cellular DNA.24,25 Members of the INSTI class include raltegravir, 
elvitegravir, and dolutegravir. Given that HIV integrase do not have human homolog, 
selective inhibition of target enzymes will result in a minimal number of adverse 
events.26,27 Commonly reported side effects include mild to moderate gastrointestinal 
effects and headaches.20 
1.4.5 Fusion Inhibitors 
Fusion inhibitors extracellularly inhibit the fusion of HIV cells onto CD4 cells or 
other host targets, thereby preventing viral activities on the host.28,29 Due to the unique 
mechanism of action, fusion inhibitors are suitable in patients with high treatment 
resistance as its action provides an extra site for targeting viral cells.28,29 The most 
frequently used fusion inhibitor is enfuvirtide. Injection site reactions, subcutaneous 








1.4.6 Chemokine Receptor Antagonist (CCR5) 
The only approved member class of Chemokine Receptor Antagonist (CCR5) is 
maraviroc, which is a prototype of CCR5.20 Maraviroc selectively and reversibly binds 
the CCR5 co-receptor, thereby preventing the binding of the V3 loop and fusion of the 
HIV cellular membrane.32 It is active against tropical HIV-1 CCR5 and is associated with 
several commonly reported adverse events such as cough, pyrexia, dizziness, rash, 
musculoskeletal symptoms, abdominal pains, and upper respiratory tract infections.33  
1.4.7 Post-Attachment Inhibitors 
  Post-attachment inhibitors are indicated in HIV-1 multidrug resistance cases in 
which HIV is irresponsive to other ART regimens. Ibalizumab is the first class of post-
attachment inhibitors approved by the FDA and is also the most recently approve 
ART.20,33 Ibalizumab is a monoclonal antibody which binds onto the extracellular domain 
2 of viral cell receptors.29 Conformational disruption associated with the binding of 
ibalizumab results in the prevention of coupling between gp120-CD4 complexes and 
CCR5 or CXCR4, which ultimately disallows viral entry and fusion.20,32 The most 
common side effects include diarrhea, dizziness, nausea, and immune reconstitution 
syndrome.34  
1.4.8 Pharmacokinetic Enhancers (PE) 
The Pharmacokinetic Enhancers (PE) class of ARTs is often referred to as 
boosting agents and constitute only a single member class called cobicistat, which acts by 
inhibiting CYPE3A.20 It is often used as a combination component with protease 





1.4.9 Combination Anti-Retroviral Therapy (cART)  
Combination anti-retroviral therapy (cART) refers to the use of two or more 
antiretroviral drugs combined based on clinical recommendations for effective treatment 
























Table 1.2 List of FDA approved Combination Anti-Retroviral Therapy (cART) 






NRTIs Based cARTs 
Combivir lamivudine and 
zidovudine 
3TC / ZDV September 27, 
1997 
Epzicom abacavir and lamivudine ABC / 3TC August 02, 2004 
Truvada Tenofovir disoproxil 
fumarate and 
emtricitabine 
FTC / TDF November 17, 
1995 
Cimduo Lamivudine and tenofovir 
disoproxil fumarate 
3TC / TDF February 28,2018 
Descovy Emtricitabine and 
tenofovir alafenamide 
FTC / TAF April 04,2016 
Trizivir Abacavir, lamivudine, and 
zidovudine 
ABC / 3TC / ZDV November 
14,2000 
PI Based cARTs 
Kaletra lopinavir and ritonavir LPV/r, LPV / RTV September 15, 
2000 
Multi-Class Combinations 
Atripla Efavirenz, emtricitabine 
and tenofovir disoproxil 
fumarate 
EFV / FTC / TDF July 12, 2006 
Complera Emtricitabine, rilpivirine, 
and tenofovir disoproxil 
fumarate 
FTC / RPV / TDF August 10, 2011 
Evotaz Atazanavir sulfate, 
cobicistat 
ATV / COBI January 29, 2015 
Prezcobix cobicistat, darunavir 
ethanolate 
DRV / COBI January 29, 2015 
Stribild elvitegravir, cobicistat, 
emtricitabine, tenofovir 
disoproxil fumarate 
QUAD, EVG / COBI / 
FTC / TDF 
August 27, 2012 
Genvoya Elvitegravir, cobicistat, 
emtricitabine, and 
tenofovir alafenamide 




Symfi Lo Efavirenz, lamivudine, 
and tenofovir disoproxil 
fumarate 
EFV / 3TC / TDF February 05, 
2018 
Symfi Efavirenz, lamivudine, 
and tenofovir disoproxil 
fumarate 





Delstrigo Doravirine, lamivudine, 
and tenofovir disoproxil 
fumarate 
DOR / 3TC / TDF 30-August-18, 
2018 
Julica Dolutegravir and 
rilpivirine 
DTG / RPV November 21, 
2017 
Dovato Dolutegravir and 
lamivudine 
DTG / 3TC April 9, 2019 
Symtuza Darunavir, cobicistat, 
emtricitabine, and 
tenofovir alafenamide 
DRV / COBI / FTC / 
TAF 
July 17, 2018 
Biktarvy Bictegravir, emtricitabine, 
and tenofovir alafenamide 
BIC / FTC / TAF February 17, 
2018 
Triumeq Abacavir, dolutegravir, 
and lamivudine 
ABC / DTG / 3TC August 22, 2014 
 
Since the introduction of cART in 1996, HIV management has improved 
significantly, resulting in improved mortality and morbidity. Evidence from clinical trials 
and observational studies has shown a significant reduction in morbidity and mortality 
among people with HIV/AIDs since the advent of cART.35-40 Over the last few decades, 
combination therapy has become better tolerated with simplified dosing (once daily fixed 
dose combinations) that improves compliance.35,41,42 cART fundamentally changed the 
epidemiology of HIV with the ability to confer stable suppression of HIV viral loads and 
boosting of the CD-4 cell counts.37 
According to the 2019 Department Of Health & Human Services (DHHS) Panel 
on Antiretroviral Guidelines for Adults and Adolescents (The Panel), effectiveness and 
preservation of future treatment options are key considerations in determining which 
classes of ARTs are combined as cARTs, as well as when a combination is used as a 
‘preferred’ regimen or an ‘alternative’ regimen.43 The choice of a cART regimen depends 
on the patients’ specific clinical conditions such as: the presence of transmitted HIV drug 





socio-economic factors, and whether it is to be used for initial therapy or for ART-naïve 
patients.43 A cART regimen is designated as  a ‘preferred’ or  ‘alternative’ regimen based 
on clinical trial evidence on efficacy in virologic suppression, tolerability, and toxicity 
profiles.43 The ‘preferred’ cART regimen is designated for use in ART-naïve patients as 
well as ART-experienced patients who are initiating cART therapy. Conversely, a 
regimen designated as ‘alternative’ cART is used when there are comparative advantages 
in terms of either efficacy, resistance, tolerability, or potential for compliance, when 
compared to the preferred regimen.43  
Three main ART combination constituents were identified by the panel for initial 
therapy in ART-naïve patients. They include (1) NNRTI-based regimens, (2) Protease 
inhibitor-based regimens, and (3) Triple Nucleoside Transcriptase based-regimens.43 
  The panel recommends the following NNRTI-based combinations:  
i) Efavirenz + (zidovudine or tenofovir or stavudine) + lamivudine as ‘preferred’ 
initial NNRTI-based regimens. 
ii) Efavirenz + (didanosine or abacavir) + lamivudine can be used as alternatives. 
iii) Nevirapine-based regimens can be used as alternatives.43  
 
Efavirenz containing cARTs are not to be used by pregnant women or women at 
reproductive age due to its teratogenicity properties.43 NNRTI based combinations have a 
well-documented high anti-virologic, high immunologic efficacy and high potential for 
compliance and adherence due to their ease of use compared to the PIs.43 They have 
fewer negative drug interactions compared to the PIs.43 NNRTI based combinations are 





disadvantages is that resistance due to NNRTIs usually cut across the entire NNRTI 
member class.43 The panel recommends lopinavir/ritonavir + (zidovudine or stavudine) + 
lamivudine as ‘preferred’ protease inhibitor-based regimens for use in PI-based 
combination regimens.43 The panel recommends a 3-NRTI regimen which consists of the 
combination of abacavir, zidovudine (or alternately, stavudine), and lamivudine to be 
used only when other combinations such as a NNRTI-based, or a PI-based regimen 
cannot or should not be used as initial therapy for reasons such as important drug to drug 
interactions.43   
1.5 Type 2 Diabetes Mellitus (T2DM) in The Unites States 
Diabetes is a chronic metabolic disorder characterized by insufficient insulin, a 
lack of insulin production, or muscular insensitivity to insulin, which is a naturally 
occurring hormone that helps in glucose utilization and metabolism.44 Diabetes consists 
of three types: type 1 diabetes mellitus, type 2 diabetes mellitus (T2DM), and gestational 
diabetes. Type 1 diabetes is characterized by autoimmune destruction of the beta cell of 
the pancreas that produces insulin, thereby resulting in an insufficient amount of insulin 
or total lack of insulin in the body.45 This condition is often hereditary, and patients 
require exogenous insulin intake to survive. T2DM is characterized by a combination of 
insulin deficiency and muscular insensitivity to insulin, resulting in the inability to 
stabilize and maintain normal blood glucose levels.44 T2DM is the most common type of 
diabetes and occurs in about 90% of people with diabetes.44   
1.5.1 Epidemiology of T2DM in the United States 
T2DM is one of the most prevalent chronic conditions and the seventh leading 





disease and a leading cause of kidney failure, nontraumatic lower extremity amputations, 
and blindness among adults in the U.S.46 In 2020, the National Diabetes Statistics Report 
noted that an estimated 34.2 million people in the U.S. are diagnosed with T2DM which 
represents about 10.5 % of the total population (all ages) and 2.8 % of the adult U.S. 
population. Over 1.5 million new cases of T2DM (7 in 1000 persons) were reported in 
2015, of which 50 % were 45 to 65 years of age.47 The economic burden of T2DM is 
high, with an estimated national cost of $327 billion in 2017.47 Approximately 73 % 
($237 billion) represents direct health care expenditures for T2DM, while 27 % ($90 
billion) were costs incurred due to overall lost productivity and diabetes related deaths.47  
1.5.2 T2DM management  
The major goal in the treatment of T2DM is to control and maintain patients’ 
blood glucose levels to a normal range using medications, good lifestyle habits, and diet. 
The first treatment approach for T2DM is weight reduction through T2DM diets and 
exercise. If symptoms and elevated blood glucose levels persist, diabetes medications 
including oral or injected dosage forms, are prescribed. Insulin is prescribed if elevated 
blood glucose levels persist after oral or injected anti-diabetes medication. Various 
classes of diabetes medications have been approved by the FDA: alpha-glucosidase 
inhibitors, amylin analogs, antidiabetic combinations dipeptidyl peptidase 4 inhibitors, 
incretin mimetics, insulin, meglitinides, non-sulfonylureas, SGLT-2 inhibitors, 
sulfonylureas, and thiazolidinediones. 
In 2013, the American Association of Clinical Endocrinologists (AACE) and the 
American College of Endocrinology (ACE) jointly recommended twelve management 





T2DM.48 This algorithm represents practice guides to clinicians with emphasis on the 
whole patient, his or her spectrum of risks and complications, and evidence-based 
treatment approaches.48  
The twelve recommended management algorithms include: (1) Continuous and 
effective lifestyle management with concurrent medical therapy, (2) Frequent blood 
glucose level monitoring to prevent therapy driven hypoglycemia and other risks that 
could lead to severe or non-severe hypoglycemia, (3) Both diet and weight-loss 
medication should be used to minimize the risk of obesity in order to prevent the 
progression of obesity-driven diabetes, (4) T2DM treatments and the hemoglobin A1C 
targeting should be individualized with a focus on the  specific risk factors of the patient 
such as age, presence of other disease conditions, adherence to treatment and motivation 
level, time since first diabetes diagnosis, life expectancy, and risk of hypoglycemia. This 
is important because clinicians depend on patients for fasting and postprandial glucose 
monitoring and reporting, (5) An A1C level of ≤ 6.5% is considered optimal in the 
management of diabetes, (6) Treatment with and choice of antidiabetic medication should 
be individualized based on the patient’s specific risk factors and other attributes, (7) 
Other comorbidities such as cardiac and cerebrovascular conditions as well as kidney 
disease should be considered while choosing antidiabetic medication, (8) In the presence 
of these comorbidities, T2DM management should be comprehensive, (9) Speedy 
normalization of blood glucose levels and management of associated comorbidities and 
risk factors should be as fast as possible to slow and avoid further complications, (10) 
Costs of medication, management and potential for adherence in terms of types of dosage 





achieve effective glycemic control, clinicians should utilize professional continuous 
glucose monitoring (CGM), and finally (12) In complying with these algorithms, all 
medication to be used should be FDA approved.48  
1.6  The Overview of Medicare and Healthcare Coverage  
Medicare is the US national health insurance program established in 1965 to 
provide health care coverage primarily to elderly people 65 years old or older who have 
over 4 quarters of work credit. It was expanded in 1972 to additionally provide coverage 
for younger adults with disabilities who qualify for Social Security Disability Insurance 
(SSDI) and have received SSDI payments for at least 24 months. It also includes 
coverage for younger adults with End-Stage Renal Disease (ESRD) or Amyotrophic 
Lateral Sclerosis (ALS) (Lou Gehrig’s disease).49 Since expansion, Medicare has 
provided health and financial coverage for over 60 million beneficiaries including the 
elderly and those under 65 with long-term disabilities.49   
Most Medicare beneficiaries live with multiple chronic conditions and/or 
disabilities and survive on limited income. In 2016, reports on the financial and clinical 
characteristics of Medicare beneficiaries showed that over 50 % of Medicare patients had 
savings below $74,450 and were living on incomes below $26,200. The report also 
showed that about 32% of Medicare beneficiaries had a functional impairment, 25% were 
in poor health, 22% had multiple chronic conditions (often 5 or more), 15% were younger 
than 65 and had long term disabilities, over 12% were 85 years old  and above, and 3% 





Medicare insurance provides coverage to beneficiaries through Part A, Part B, 
Part C and Part D insurance plans. Medicare Part A covers in-patient care services, 
Skilled Nursing Facilities (SNF), some home health services, and hospice care. Medicare 
Part B covers services such as physician visits, outpatient services, and some home health 
and free preventive services such as prostate cancer screening and mammography.50 Part 
C, also known as the Medicare Advantage program, constitutes enrollment in private 
insurance plans such as health maintenance organization (HMO) or preferred provider 
organization (PPO) while also enrolled in Part A and Part B. These beneficiaries obtain 
prescription drugs through Part D.50 Part D was established in 2006 and provides 
coverage for outpatient prescription drugs through contracting with private insurance 
plans that offer retail prescription drug coverage to Medicare beneficiaries.50 Contracting 
private insurance plans includes stand-alone prescription drug plans (PDPs) which work 
alongside the original Medicare plans and the Medicare Advantage Plans with 
Prescription Drug coverage (MA-PDs). These are built into the Medicare advantage 
plan.50 A summary of current deductible amounts and coinsurance rates for Part A and 











Table 1.3: Summary of current Medicare Part A and Part B coverage and copays, 2020 
Coverage Patients Co-pay Medicare Co-pay 
Medicare Part A 
Hospital Care (Inpatient) 
i. Day 1 to 60 
ii. Day 60 to 90 
iii. Day 90+ (Lifetime Reserve 
Days) 
iv. Days after lifetime reserve 
days 
 
i. $1,408 deductibles 
ii. $352 coinsurance 
per day 
iii. $704 coinsurance 
per day 





iii. Balance  
iv. No cost 
Skilled Nursing Facility Care 
i. First 20 days 
ii. Days 21 to 100 
iii. Days after 100 days 
 
i. No cost 
ii. $176 
iii. All cost 
 
i. All cost 
ii. Balance t 
iii. No cost 
Home Health Services 
Part-time or intermittent skilled 






i. Palliative care (comfort care) 
ii. Prescription drug from 
outpatient 
iii. Inpatient respite care 
 
i. No cost 
ii. $5 per prescription 




i. All cost 
ii. Balance 
iii. Balance 
Medicare Part B 
Medical Services 
Physician’s services, Outpatient care 
Home health services, Durable 
medical equipment (DME), Mental 
health services, Other medical 
services 
 
$198 deductible  
20% co-insurance if the 




Balance after $198 
deductibles 
Durable Medical Equipment and 
Supplies 
20% coinsurance for 
Medicare-approved 
amount after $ 198 
deductible is met. 
Balance after $198 
deductibles 
Outpatient Hospital Services 20% coinsurance for 
Medicare-approved 
amount after $ 198 
deductible is met 
Balance after $198 
deductibles 
Outpatient Medical and Surgical 
Services and Supplies 
20% coinsurance for 
Medicare-approved 






X-rays, casts, stitches, outpatient 
surgeries 
amount after $ 198 
deductible is met 
Laboratory tests 
Blood test, urinalysis, Human 
Papillomavirus, Lab pap test, 





100 % of the cost 
of the approved 
Breast Cancer Screening: 
Mammogram 
i. Once a year for women 35-
39 years old 
ii. More than once a year 
 
i. No cost 
 
ii. 20% coinsurance 
for Medicare-
approved amount 
after $ 198 
deductible is met 
 





Home Health Services 
Medical social services, part-time or 
intermittent home health aide 
services, DME and medical supplies 




100 % of the cost 
of the approved 
care 
 
1.6.1 Medicare Population and HIV/AIDS  
Medicare is an important source of health coverage for people with HIV. It is 
currently the largest source of federal government healthcare spending on HIV, providing 
health coverage for one quarter of all HIV patients currently under care.49   
1.6.1.1   Epidemiology of HIV/AIDS among the Medicare population 
In 2014, 0.4% of all Medicare beneficiaries with fee-for-service redeemed claims 
for HIV/AIDS treatment.52 The prevalence of HIV/AIDS in the US has increased over 
time owing to the availability of earlier diagnoses, improved therapy, and steady 
incidence rate.53,54 As the number of HIV/AIDS survivors increases following 
advancements in treatment, and a steady number of new infections grows, the number of 





beneficiaries with HIV rose from 42,500 in 1997 to 120,000 in 2014.49 Consequently, the 
number of diagnosed and undiagnosed elderly Medicare beneficiaries has also increased 
because a large segment of the HIV population has grown older and now qualifies for 
Medicare.49 Approximately 21% of Medicare beneficiaries with HIV are elderly (65 
years and above) and qualify for Medicare based on age only. The remaining 79% 
includes younger, disabled individuals who qualify for Medicare based on disability and 
are receiving SSDI payments.49 However, it has been estimated that over 50% of the 
individuals with HIV will be over 50 years of age in the near future55, thus indicating an 
upward trajectory in the prevalence of HIV among the elderly population.  
In addition, unprotected sexual behavior still plays a huge role in HIV infection 
among the elderly who are sexually active late into life.56,57 Elderly individuals are 
generally perceived as a low-risk population, and consequently, providers often do not 
routinely collect and record their sexual habits and activities. In the same vain, elderly 
people don’t readily share their sexual habits with providers.55,58,59 Furthermore, the 
physiology of the older population changes in ways that increase susceptibility to HIV 
infection among those that remain sexually active.  Post-menopausal women do not 
worry about becoming pregnant and are more likely to have unprotected intercourse.58,60 
Age related thinning and dryness of the vaginal epithelium can expose vaginal epithelial 
tissues to abrasions, and consequently facilitate HIV infection.58 It has been shown that 
the postmenopausal cervix may undergo immune changes, producing target cells such as 
CD4+ and CCR5+ T-cells with a greater number of inflammatory factors which 





Racial disparity in the prevalence of HIV/AIDS among Medicare beneficiaries 
has been reported. Medicare beneficiaries with HIV are disproportionately African 
American. They have the highest prevalence of infection (1.6%), followed by Hispanics 
(0.8%), and Indian/Alaska Native (0.4%). Caucasians and Asian/Pacific Islanders had the 
lowest prevalence of all races (0.2%).52 Other relevant demographic disparities have also 
been recognized.  Medicare beneficiaries with HIV are disproportionately men (74%) and 
mostly dual eligible for both Medicaid and Medicare (69%).49 
1.6.1.2    Health care benefits for HIV-positive Medicare beneficiaries 
 Medicare provides a wide range of coverage for several healthcare services such 
as hospital care, medical care and physician visits, and prescription drugs. However, 
under the traditional Medicare Parts A and B, beneficiaries with HIV/AIDS are not 
covered for all the necessary health care services. Also, there is no OOP expenditure cap 
associated with Medicare parts A and B. As a result, the Medicare Part D plan provides 
much needed cost-sharing assistance specifically for Medicare beneficiaries with 
conditions that involved treatment with costly medications, including those with HIV. 
Part D subsidizes prescription drug costs for beneficiaries enrolled in private plans 
through low income subsidy (LIS) programs with catastrophic benefits. In 2014, 
approximately 77 % of Medicare beneficiaries with HIV qualified for the LIS program.  
Consistent with the Center for Medicare and Medicaid (CMS) guidelines and the 
Affordable Care Act (ACA) codified law which designated Anti-retroviral therapy (ART) 
as one of the ‘six protected’ drug classes, Medicare Part D plans are required to cover all 
ARTs including those in the coverage gaps.49 In addition to ARTs coverage, Medicare 





screening. Medicare provides coverage for once-a-year voluntary HIV tests for Medicare 
beneficiaries within the age range of 15 to 65 years old and pregnant beneficiaries, 
regardless of the risk of HIV infection. Beneficiaries younger than 15 and older than 65 
are only covered if they are at increased risk of HIV infection.49   
In addition to Medicare benefits, HIV positive beneficiaries benefit from 
supplemental health coverage from Medicaid, the Ryan White HIV/AIDS Program,63  
and other payers. Low income dual eligible beneficiaries benefit from Medicaid 
supplemental coverage for premiums and cost sharing.49  Eligible beneficiaries may 
receive payments of health coverage expenses from the Ryan White HIV/AIDS Program 
and additional services, such as case management and transportation assistance. 
Specifically, the Ryan White HIV/AIDS Program provides primary medical care, social 
support services, as well as funding of medications for low-income HIV patients who 
may be underinsured.63 The program is committed to reducing HIV transmission among 
HIV positive patients living in hard-to-reach areas. This is accomplished  through grant 
provisions for HIV care to relevant local communities and states, medication provision, 
and prevention education and aids to reduce transmission.63 More than 50 % of people 
with HIV receive HIV treatment and care from the Ryan White HIV/AIDS Program, 
which means that over 500,000 patients receive HIV care and services through the 
program annually.63  
1.6.1.3 Medicare spending on HIV 
 Since the beginning of the HIV epidemic, the combined global and domestic 
federal expenditure for HIV has risen to $34.8 billion in the 2019 fiscal year.64 Growth in 





mandatory treatment policies.64 Medicare has surpassed Medicaid in funding for HIV 
over the years due to the growing number of HIV patients who survive the infection 
reaching the age of eligibility for Medicare. Since the introduction of Medicare Part D 
which provides cost sharing assistance to Medicare beneficiaries and dual eligible with 
HIV, Medicare has become the agency of the federal government with the largest source 
of funding for HIV care.49 In the 2016 fiscal year,  2% of Medicare expenditures were 
directed toward HIV care, which is a total of $10 billion. This represents approximately 
51% of all federal spending on HIV care. In 2014, the average Medicare per capita 
spending for Medicare beneficiaries was $45,489 of which 59% ($26,761) constituted 
prescription drug spending through Part D Medicare plans. 49 It is worthy of note that 
annual per capita Medicare spending in 2014 was significantly higher among Medicare 
beneficiaries who are recipients of Low Income Subsidy (LIS) compared to those who 
are not. 49 
1.6.2 Medicare population and diabetes 
In a study conducted by Andes et al which exclusively used Medicare data for 
1999-2017 showed that the national prevalence of diabetes among Medicare fee-for-
service beneficiaries rose from 23.3% in 2001 to 31.6% in 2015.65 Prevalence varies 
among beneficiaries of different racial identification. African Americans, Hispanics and 
Asian/Pacific Islanders have prevalence rates that are significantly higher than the 
national prevalence rate, while the Caucasian Medicare beneficiaries have a prevalence 
below the national prevalence rate- 29.2%.65 African-Americans have the highest 
prevalence (47.4), followed by Hispanics (46.3) and Asian/Pacific Islanders (43.5) 





recorded at the rate of 3.0% in 2015 across all ethnicities.65 Incidence rates vary across 
race according to Andes et al, with incident rates among Hispanics being (5.2%), African 
Americans (5.1 %) and Asian/Pacific Islanders (4.7 %).  All of these were well above the 
national incidence rate of  3.0%, whereas the Caucasian Medicare beneficiaries incidence 
rate (2.8 %) was below the national rate.65 Among beneficiaries aged 68 and above, the 
overall prevalence and incidence of diabetes were 31.6% and 3.0% respectively. 65 
Gender disparity in national prevalence and incidence rates were also reported. 
Men have a higher national prevalence rate (34.3) and incidence rate (3.5) than women. 
This variation was sustained from 2001 through 2015. 65 When assessing the modifier 
effect of race on prevalence rates among men and women, results showed that the 
prevalence rate was higher in men among Caucasians and Asians/Pacific Islanders, and 
higher in women among African Americans and Hispanics. 65 
1.6.2.1  Medicare coverage and spending for T2DM 
Generally, Medicare Part B and Part D provide coverage for medications and 
necessary supplies needed for diabetes management. Medicare Part B covers fasting 
blood glucose screening once a year and two times a year for high risk beneficiaries. 
High risk beneficiaries are those with a genetic family history of diabetes and those with 
other chronic conditions that are risk factors to diabetes – high blood pressure, obesity, 
history of pre-diabetes (abnormal tri-glyceride levels and history of high blood sugar 
levels), and abnormal cholesterol.  
As described in Table 1.3, beneficiaries with diabetes are not charged for 





20% copay for the doctor’s visit. Medicare Part B also covers supplies such as sugar 
monitoring equipment, lancet devices and lancets, blood sugar test strips and solutions. 
Medicare may cover external insulin pumps and insulin DME, and medical nutritional 
therapy for diabetes, however, patients may pay 20% of the Medicare approved amount 
after the yearly deductible as shown in Table 1.3. For beneficiaries with high risk, 
Medicare Part B provides coverage for the initial 10-hour diabetes self-management 
education and training, as well as a two-hour post training follow up each year. During 
complications such as foot diseases, Medicare Part B provides coverage for professional 
foot care every six months (so long as the beneficiary did not visit a footcare professional 
for another reason) and special footwear.  
Medicare Part D provides coverage for diabetes medications and supplies for 
enrolled beneficiaries with diabetes. Diabetes medications covered include various 
classes of antidiabetic medications such as sulfonylureas, biguanides, thiazolidinediones, 
alpha glucosidase inhibitors, and injectable insulin which are not associated with insulin 
infusion pumps (Medicare Part B covers insulin administered with insulin infusion 
pumps as DME). Medicare Part D may also cover insulin associated supplies such as 
syringes and needles, gauze and alcohol swabs. Medicare beneficiaries on Part D may 
pay certain coinsurance or Part D deductibles depending on which private plan they are 
enrolled in - PDP or MA-PDP. 
Medicare beneficiaries with diabetes experience significant challenges and 
financial burdens regarding access to care and OOP expenses.66 The increasing cost of 
prescription drugs for different disease conditions, including diabetes, has been a huge 





patient and Medicare expenditure for diabetes. Between 2007 and 2017, expenditure on 
insulin alone by Medicare, private insurance plans, and patients has risen from $1.4 
billion to $13.3 billion.66 This translates to an increased cost from $862 in 2007 to $3,949 
per insulin user which represents about a 358 % increase.66 Considering the increased 
number of Medicare beneficiaries using insulin and the increased price of insulin, the 
aggregate total OOP expenditure increased from $236 million to $968 million between 
2007 and 2016. This represents an 81% increase in OOP expenditure per beneficiary 
between 2007 and 2016 ($324 to $588).66  
1.7 HIV Infection, Treatment and Metabolic Syndrome.   
Diabetes and complications of glucose metabolism are associated with HIV 
infection and treatment.67 Three different kinds of patients exist based on when diabetes 
or HIV were diagnosed. Some patients were diagnosed with diabetes at the onset of HIV, 
some have pre-existing diabetes before HIV diagnosis, and some developed diabetes or 
have signs of diabetes after the initiation of ART.68 The underlying pathogenesis of 
metabolic dysregulation is different among these groups of patients.68  
After HIV diagnosis, HIV patients commonly present with metabolic 
dysregulation such as dyslipidemia, lipodystrophy, metabolic syndromes and 
dysregulated glucose metabolism.68 In addition to HIV infection, HIV patients are 
predisposed to the same risk factors for T2DM and metabolic syndrome. These risk 
factors include older age, duration of HIV infection, high viral load, low CD4 count, 
being a male, high waist/hip ratio, and ethnicity.69,70  Furthermore, impaired glucose 
tolerance and insulin resistance are key parts of diabetes pathogenesis in patients with 





iatrogenic. Anti-retroviral-related T2DM, lipodystrophy, and metabolic dysfunction 
including insulin resistance have been reported to have increased among patients treated 
with ARTs.74 
HIV patients could have an effective viremic control but may be highly 
predisposed to metabolic syndrome. This is explained by the interaction between HIV 
infection, antiretroviral therapy (ART), and inflammation. Figure 1.1 shows the 
interaction between HIV infection, HIV treatment with ARTs and inflammation, which 
independently and collectively result in several chronic conditions such as cardiovascular 
disease, dyslipidemia, insulin resistance, and lipodystrophy.75 There is existing evidence 
that shows that the activation of the immune system following either HIV infection or 
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1.7.1  Biology of HIV infection, ARTs, and metabolic syndrome 
According to the World Health Organization’s (WHO) provisional report, 
metabolic syndrome consists of a combination of metabolic dysfunctions resulting from 
insulin resistance, obesity and impaired glucose regulation manifesting as impaired 
glucose tolerance.76 Typically, the presence of at least five metabolic dysregulation 
components such as elevated triglyceride levels and blood glucose levels, central obesity, 
high blood pressure and decreased high density lipoprotein levels constitutes metabolic 
syndrome diagnosis.77 The cascade of physiological processes that triggers metabolic 
syndrome involves factors such as peroxisome proliferator‑activated receptor gamma 
(PPAR), tumor necrotic factor‑alpha (TNF), adipose tissue, interleukins, fuel oxidation, 































Figure 1.2: Pathophysiology of metabolic syndrome from HIV infection, ARTs and other 
factors 
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1.7.1.1 Metabolic syndrome and HIV infection  
HIV infection is associated with metabolic syndrome through two major 
physiological pathways which include, (1) cellular apoptosis and the body’s 
inflammatory response to the HIV infection which leads to insulin resistance and, (2) 
Mitochondria dysfunction induced by cell apoptosis. 
HIV specific inflammatory markers have been implicated in several chronic 
disease conditions including T2DM.79 In addition, the body’s response to inflammation 
results in the suppression of anti-diabetic functions of adiponectin, thereby impairing 
tissue sensitivity to insulin leading to hyperglycemia and T2DM. 80 Cellular apoptosis 
involves the binding of the HIV proteins gp120 and gp41 to the CD4/CXC chemokine 
receptor 4, thereby mediating apoptosis through the fusion/hemifusion process referred to 
as gp4 induced hemifusion. 80 Studies have shown that gp41 induced hemifusion derives 
virion-induced apoptosis which triggers inflammatory mediators such as, TNF‑α, 
interleukins and C‑reactive protein (CRP) levels, which are associated with impaired 
muscle response to insulin and adiponectin suppression (an adipose-specific collagen-like 
molecule with anti-diabetic activity) thereby resulting in T2DM development.81  
 Cytotoxic protease secreted during HIV infection causes apoptosis through 
cellular proteins such as actin, Bcl2, and procaspase. 80 Activation of cytotoxic proteases 
depends on cytochrome c which is exclusively domicile in the mitochondria. 80 During 
activation following apoptotic signal, ions in the mitochondria are distributed 
asymmetrically on both sides of the internal sections of the mitochondria membrane. 80 
The mitochondrial permeability transition pore complex (PTPC) opens, resulting in the 





release of apoptogenic factors which includes the cytochrome c and procaspase‑9. 82 83 
Mitochondrial disruption and subsequent host cell apoptosis which results from 
uncontrolled release of cytochrome c triggers host inflammatory response. 82 The 
inflammatory response involves the release of inflammatory mediators, such as 
interleukins and C-reactive protein (CRP), at levels which suppress adiponectin 83 and 
induce muscular insulin resistance 82 resulting in metabolic syndrome (Figure 1.2).   
1.7.1.2 Metabolic syndrome and ARTs 
 The use of ART and its combination regimens has shown great clinical benefits in 
HIV treatment. However, long term use has been associated with metabolic syndrome as 
an adverse event. Furthermore, the use of these therapies can trigger a cascade of 
activities that results in the development of dyslipidemia, lipodystrophy and 
mitochondrial dysfunction. Specifically, ARTs stimulates an increased release of TNF‑α 
which contributes to the impairment of fatty acid metabolism, lipid oxidation, and 
suppression of lipolysis.84 This impact on lipid metabolism results in altered fat 
distribution and major alterations in the lipid profile, which is  characterized by an 
increase in the levels of triglycerides (hypertriglyceridemia), a low‑density lipoprotein 
cholesterol, and a decrease in HDL cholesterol.85 Altered glucose homeostasis has also 
been reported during HIV treatment with ARTs. In vitro studies suggested a physiologic 
process that involves an insulin sensitive glucose transporter that is responsible for 
glucose uptake - GLUT‑4. Indinavir inhibits GLUT‑4, thereby preventing muscular and 
adipocyte’s glucose uptake. 86,87  Although all member classes of PIs inhibit GLUT-4, 





syndrome develops in patients treated with ARTs through two major pathways which 
may include lipodystrophy, dyslipidemia, and mitochondria dysfunction.  
 Lipodystrophy and dyslipidemia are the two major clinical manifestations of 
metabolic syndrome. Lipodystrophy results from ART and HIV infection induced 
alterations in lipid metabolism89 while dyslipidemia is characterized by 
hypertriglyceridemia, hypercholesterolemia, and low levels of HDLs 90, which results 
from impaired lipoprotein metabolism.91 PI related metabolic syndrome occurs due to PI-
induced alteration in the expression of sterol regulatory element‑binding protein‑1 and 
PPAR‑γ which are key elements required for cellular adipocytes differentiation.92 Thus, 
in the process, cellular adipocytes differentiation is inhibited which leads to impairment 
of lipid metabolism and consequently lipodystrophy and dyslipidemia.92 Along the line, 
dyslipidemia and hyperglycemia develop as well as hypertriglyceridemia. 
Hypertriglyceridemia is known to be associated with acute pancreatitis which is 
characterized by beta cell function disruption and the subsequent development of 
T2DM.93 Another pathway through which use of ARTs could be linked to metabolic 
syndrome is mitochondrial toxicity or mitochondrial disruption which involves 
polymerase-C hindrance and draining of mitochondrial deoxynucleic acid (DNA).94 





First, this chapter presents the literature review of relevant peer reviewed articles 
that evaluated HIV treatment with PIs and the risk of developing T2DM. Reviewed 
studies were cross-sectional studies, case-control studies, cohort studies, and randomized 
control trials. The characteristics of these studies are summarized in Table 2.1 and Table 
2.2. Second, this chapter reviews literature regarding the disparity in race/ethnicity as 
applies to the risk of developing T2DM among HIV/AIDS positive patients treated with 
PIs. Third, this chapter details the review of literature regarding additional costs of 
T2DM comorbidities among patients with HIV/AIDS. Finally, the study objectives, 
specific aims, and hypothesis as well as significance and innovation are discussed in this 
chapter. 
2.1  Protease Inhibitors and Development of T2DM 
The safety and tolerability of protease inhibitors (PI) has been widely investigated 
and findings are largely controversial in terms of the risk of T2DM, insulin resistance and 
related metabolic syndromes. Table 2.1 summarizes some characteristics of studies that 
report that use of PIs is associated with the risk of T2DM. Among reviewed cross-
sectional studies, Barry et al studied 164 HIV patients and compared patients on PI-based 
combination therapy with those on non-PI based combination therapy. They found that 





combinations and their seronegative counterparts. 95 Furthermore, Behrens et al showed 
that PI-based ART combinations were significantly associated with impaired glucose 
tolerance. Non-combination PI-based ART and their associations with the risk of T2DM 
have also been widely explored.96 Andrew Carr et al compared the occurrence of 
peripheral lipodystrophy, hyperlipidemia, and insulin resistance in 116 patients receiving 
protease inhibitors versus 32 HIV patients who are protease inhibitor naïve. 97 They 
found that protease inhibitor therapy was associated with significantly higher triglyceride 
levels.97 Maganga et al compared the risk of glucose metabolism disorder among HIV 
positive ART-naïve patients and  HIV positive patients on various ARTs, such as 
lopinavir and ritonavir, nevirapine, efavirenz, tenofovir, stavudine, zidovudine and 
seronegative patients. This finding indicates that patients on ARTs have 5-fold greater 
odds of having glucose metabolism disorder compared to ART-naïve groups and 
seronegative patients. 98  Samaras et al reported that HIV patients receiving protease 
inhibitors were more commonly presenting with metabolic syndrome, which is associated 
with a nine fold prevalence of T2DM.6   
 In a case-control study conducted in Taiwan, 1,534 HIV patients enrolled in a 
prospective cohort study and were followed for 14 years.99 Out of the eligible 824 HIV 
positive patients, only 50 patients developed diabetes. Lo et al matched two controls per 
case and they found that exposure to protease inhibitors were significantly associated 










  Table 2.1: Characteristics of selected studies that reported significant association between use of PIs and T2DM 
Author 
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Among reviewed cohort studies, Capeau et al, followed 1,046 patients in France 
and found that short-term exposure to indinavir is associated with increased incidence of 
T2DM.74  In Ledergerber et al, 6,513 patients were followed for 6 years prospectively 
and it was found that indinavir demonstrated a strong association with the risk of 
T2DM.100 In a cohorts study of 221 HIV infected patients who were followed for 5 years, 
Tsiodras et al show that the use of PIs is associated independently to elevated glucose 
and triglyceride levels.102 In another study, Hughes et al followed a cohort of 496 HIV 
patients in Canada for 6 years and found that the use of PIs was significantly associated 
with the development of diabetes.103 Justman et al compared the use of PIs with RTIs in a 
cohort of 1,785 non-pregnant HIV positive women who were followed for four years in 
California. The study concluded that patients on PIs have a threefold increase in 
incidences of diabetes compared to RTI users.104  
Furthermore, when PI users were compared with PI naïve HIV patients, the result 
persisted in Carr et al. who reported that hyperlipidemia and impaired glucose were 
significantly common among PI users compare to PI-naïve HIV patients when followed-
up at the end of  2 years.105  Moreover, in a prospective cohort of 231 HIV patients that 
were  followed for over 3 months, Calza et al. reported that the use of PI-based cARTs 
are associated with elevated serum triglycerides. Ritonavir or lopinavir/ritonavir, 
specifically, were found to be predictors of an increase in serum triglyceride levels.106  
The effects of PI were further examined using insulin resistance to measure 
outcomes in a cohort study of 41 patients followed for 4 months by Mulligan et al and his 
colleagues. They reported that in patients treated with PI therapy, insulin levels doubled.  
Additionally, fasting glucose and triglyceride levels also increased significantly.107
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Moreover, in a cohort study of 235 patients, those switching from lopinavir/ritonavir to 
an atazanavir based ritonavir-boosted (ATV/r) or an un-boosted regimen after an initial 
48 weeks, had a significant decrease in mean glucose levels and insulin resistance.111 
This study suggests that patients who have achieved initial viral suppression while on 
lopinavir/ritonavir + two NRTIs can switch to atazanavir + two NRTIs to ensure recovery 
and improvement in both lipid and glycemic metabolism.111 These studies further buttress 
the relationship between lopinavir/ritonavir based medication and glycemic metabolic 
syndrome or diabetes. Furthermore, Tripathi et al. utilized a marginal structural modeling 
approach to compare incidence of diabetes in HIV patients on HAART and their matched 
seronegative counterparts. They found that cumulative exposure to protease inhibitors are 
significantly associated with a higher risk of diabetes.108  
The association between PIs use and development of diabetes is stronger in the 
presence major confounders and strong risk factors for diabetes such as Hepatitis C Virus 
(HCV) infection and increasing age. In a cohort study of 1,230 HIV patients, both the 
HCV infection and the use PI were independently associated with an increased risk of 
diabetes. Additionally, the  risk of developing diabetes was highest among PI users with 
the HCV co-infection.112 In a 3 year retrospective cohort study of 101 patients Salehian et 
al. found that the likelihood of developing diabetes among protease inhibitor users 
increased with age and may also have a racial disparity.109  
In a randomized controlled trial that examined the effect of ARTs on the risk of 
developing diabetes, Woerle et al. evaluated beta-cell function, glucose production, 
glucose disposal and free fatty acid turnover in 13 HIV infected volunteers exposed to a 
protease inhibitor based cART as well as 14 healthy volunteers monitored over 12 weeks. 
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The results showed that exposure to a protease inhibitor based cART was significantly 
associated with impaired glucose tolerance.110 
Conversely, several cohort studies have reported contradicting results. Table 2.2 
summarizes some characteristics of studies that report contradicting results. In a 
longitudinal cohort study of 1,748 HIV-infected Thai patients followed for 9 years by 
Opas et al., univariate cox proportional regression showed that use of protease inhibitors 
such as Lopinavir/ritonavir, Atazanavir/ritonavir and indinavir were not significantly 
associated with the risk of developing T2DM.113  In an observational, prospective, 
multicenter study of 1,594 HIV positive patients, Riyaten et al. reported that, based on a 
multivariate cox proportional hazard model, the use of protease inhibitors such as 
ritonavir, combination of nevirapine, emtricitabine combination and ritonavir-boosted 
indinavir, as well as combination of zidovudine, lamivudine and ritonavir-boosted 
indinavir were not associated with the risk of T2DM development in the patients.114 
According to Squillace et al., lopinavir/ritonavir, fosamprenavir/ritonavir, 
indinavir/ritonavir, saquinavir/ritonavir were not significantly associated with the risk of 







Table 2.2 Characteristics of studies that did not detect an association between use of PIs and T2DM 
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Furthermore, in the ‘Women’s Interagency HIV Study (WIHS), which is a multicenter 
prospective cohort study, Tien et al. compared 1,524 HIV infected women who were on a 
protease inhibitor based HAART to those not on a protease inhibitor based HAART, and 
564 seronegative women, show that there is no significant difference in the incidence of  
diabetes between the groups after a 1 year follow-up period.115  
In Abraham et al., use of PI- Lopinavir was not associated with the risk of 
developing T2DM.116 In Butt et al., multivariate result of the 3,327 HIV-infected and 
3,240 HIV-uninfected subjects show that protease inhibitors are not a predictor of 
diabetes after adjusting for other covariates.117 Almeida et al. did not detect a significant 
association between the use of protease inhibitors and the risk of diabetes.118 Also, Wand 
et al. compared the use of NNRTI with a combination of PI + NNRTI, and PI only in a 
cohort study and reported that neither the use of PI + NNRTI, PI, or NNRTI were 
significant predictors of diabetes.119 Similarly, long term exposure to protease inhibitors 
was not found to be a significant predictor of diabetes in a large multicentered Data 
Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort study of 32,437 
patients followed over a 6 year period.122  In patients receiving protease inhibitors 
containing  cART regimen, Gomes et al., found that the use of a regimen containing a 
protease inhibitor is not significantly associated with the risk of impaired glucose or 
diabetes.120 This result persists in Rasmussen et al., which reported that the use of 
protease inhibitors such as indinavir, nelfinavir, atazanavir, ritonavir +/−lopinavir are not 




Furthermore, several studies reported that use of a protease inhibitor confers a 
protective effect from the risk of diabetes among patients with HIV/AIDS.  In Tien et al., 
exposure to ritonavir and nevirapine were both associated with a reduced risk of 
diabetes.115 Similarly, De Wit et al. concluded that exposure to ritonavir was associated 
with a decreased risk of diabetes.122 Furthermore, in another cohort study of 6,195 HIV 
patients, Spangnuolo  et al. reported that HIV patients treated with atazanavir or 
darunavir were less likely to develop diabetes.123  
2.2 Race/ethnicity Disparity in PI use and Development of T2DM 
Racial variation in the prevalence of HIV/AIDs is well documented in the 
literature with the highest prevalence reported among African Americans. 124 Nearly half 
of all HIV/AIDS incidents occur among African Americans with a prevalence rate 8 
times higher than in Caucasians.124 African-Americans are also shown to have poorer 
HIV infection prognoses and death rates that are 9 times higher than those of 
Caucasians.125-127 Several studies suggest that this racial disparity in health indices is a 
function of various factors related to demography, socio-economy, access to quality 
healthcare, individual habits, as well as attitudes and level of trust in the healthcare 
system.125-127  
Even though access to HIV care is critical for the survival of HIV/AIDS patients, 
access to ARTs and HIV treatment is not equitably distributed among HIV/AIDS patients 
in the US. Gebo and his colleagues examined racial disparity in receipt of HAART in 
2001and found that racial disparities do exist.5 Furthermore, Fleishman et al. concluded 
that being a younger African American female is associated with lower receipt of 
ART.128 Palacio and his colleagues reviewed the literature and concluded that, based on 
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available evidence, HIV positive minorities have lower ART use compared to HIV 
infected Caucasians.129 Despite Medicaid’s potential for equitable access to care through 
equity in insurance coverage for all enrollees, there is evidence that racial/ethnic disparity 
in receipt of HAART exists between both Medicaid beneficiaries enrolled in Fee-For-
Services and managed care130-132.  
Given evidence of racial disparity in HIV/AIDS treatment, potential disparity in 
HIV/AIDS treatment outcomes and adverse events such as the risk of diabetes may exist. 
An effective risk management in the clinical use of ART would require proper 
consideration of how the risk of diabetes following the use of ART varies among HIV 
infected patients of different ethnicities. Based on the literature review, no studies have 
examined possible racial/ethnic disparity in the development of diabetes following PI 
based treatment among HIV infected Medicare recipients. To fill this knowledge gap, we 
therefore seek to examine the racial disparity in the development of diabetes among HIV 
positive Medicare patients who are on PI. 
2.3 Economic Burden of Comorbid T2DM   
Improvement in the methods of HIV detection, early diagnosis, and treatment 
with ARTs has resulted in improvement in patient’s survival and, consequently, a steady 
growth in the population of HIV survivors. 133 Access to potent ARTs reduce morbidity 
and mortality which increases the life expectancy among patients with HIV/AIDS. 
Consequently, the number of elderly patients with HIV/AIDS increases proportionately. 
HIV/AIDS infected patients over the age of 65 are predisposed to age-related chronic 
complications in addition to treatment-related adverse events.68 Comorbidities with 
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HIV/AIDS among the elderly not only constitute challenges in clinical management but 
may also cause a major economic burden for patients and insurers.  
HIV/AIDS and ART-associated diabetes and other metabolic syndromes are 
commonly encountered in clinical management of HIV/AIDS and is most likely to occur 
as treated patients grow older.6 Comorbidities with HIV/AIDS may pose significant 
clinical challenges as well as an economic burden on the US Medicare system given the 
increasing number of surviving elderly with HIV/AIDS- the population demographic that 
is most predisposed to diabetes and other age related chronic conditions.7 Studies show 
that 83% of elderly HIV patients had at least one comorbidity compared to 69% in 
elderly non-HIV patients and  63% in younger HIV patients.134 A longitudinal study of 
Medicare beneficiaries reports that the prevalence of diabetes in elderly patients with 
HIV is 19.4% and  27.3% (hyperlipidemia).135 In Taiwan, the prevalence of diabetes 
among men and women 60 years old and above are 21% and 16.7% respectively.136 
Economic burden due to diabetes comorbidity among HIV/AIDS patients has 
been reported. Among HIV positive Medicare beneficiaries enrolled in California 
Medicare, the mean per capital expenditure for HIV/AIDS patients with complicated and 
uncomplicated diabetes is as high as $92,992 and $66,275 respectively per annum.7 
Although, the prevalence and expenditure of diabetes comorbidity in California is 
known, the current national economic burden of diabetes comorbidities among HIV 
positive Medicare beneficiaries is not known. As clinical management of HIV/AIDS is 
progressively expanding to include chronic and metabolic complications as well as 
treatment-related adverse effects, this study seeks to specifically explore the national 
economic burden of diabetes comorbidity in terms of total OOP cost to the patients, total 
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prescription cost, total Medicare cost, total inpatient cost, total outpatient cost and overall 
total healthcare costs. Understanding the economic burden of diabetes comorbidity on the 
Medicare system and individual patients could motivate the development of policy and 
regulatory strategies that drive efficient resource allocation to contain the additional 
economic burden on patients and the Medicare system. 
2.4  Literature Gaps 
Based on the review of literature, the following literature gaps were identified and 
have informed the objectives of this study.  
 Evidence of an association between PIs use and the development of T2DM 
has been largely debated in research across the world. Given the available 
inconclusive and controversial evidence, more research is needed to support 
or refute currently available evidence in order to draw conclusions.  
 To date, no study has explored this association among Medicare beneficiaries. 
Thus, evidence of PIs use and the odds of developing diabetes among the 
Medicare population with HIV/AIDS is unknown.  
 To date, no study has examined possible racial/ethnic disparity in the 
development of diabetes following treatment with PI among HIV infected 
Medicare beneficiaries.  
 To date, no study has evaluated the national economic burden of comorbid 






2.5  Study Objectives and Specific Aims  
The objectives of this project were to (1) examine the association between 
treatment with PIs and the risk of developing T2DM among Medicare beneficiaries living 
with HIV/AIDS, (2) assess racial/ethnic disparity in odds of developing T2DM among 
HIV/AIDS positive beneficiaries treated with PI and (3) to determine the economic 
burden of comorbid T2DM among Medicare beneficiaries living with HIV/AIDS 
2.5.1 Aim 1: Treatment with PI and development of T2DM 
Aim 1: To assess the association between treatment with PIs and development of 
T2DM among Medicare beneficiaries with HIV/AIDS.  
Use of PI has been associated with the risk of metabolic syndrome which includes 
development of T2DM among patients with HIV/AIDS. While this evidence is currently 
being debated globally, evidence among the Medicare population is yet to be reported. 
We, therefore, hypothesize an increased odds of developing T2DM among Medicare 
HIV/AIDS positive beneficiaries treated with PIs compare to those treated with non-PIs 
and those who had no-ARTs. 
Hypothesis 1.1: We hypothesize that HIV/AIDS positive Medicare beneficiaries 
treated with PIs are more likely to develop T2DM compared to HIV/AIDS 
positive beneficiaries treated with non-PIs. 
Hypothesis 1.2: We hypothesize that HIV/AIDS positive Medicare beneficiaries 
treated with PIs are more likely to develop T2DM compared to HIV/AIDS 
positive beneficiaries who had no-ARTs. 
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2.5.2  Aim 2: Racial disparity in development of T2DM following treatment with PI  
Aim 2: To examine racial/ethnic disparities in development of T2DM following 
treatment with PIs among Medicare beneficiaries with HIV/AIDS.  
Racial disparity in the epidemiology of HIV infection and treatment have been reported. 
As a result, racial disparity in development of T2DM following treatment with PIs may 
exists. We, therefore, hypothesized that the odds of developing T2DM following PI use 
may vary among Caucasian and African American HIV/AIDS positive Medicare 
beneficiaries. 
Hypothesis 2.1: Comparing PIs versus non-PIs therapy group, we hypothesize that 
the odds of developing T2DM following treatment with PIs is higher among 
African American race compared to the odds of developing T2DM after treatment 
with PI among the Caucasian beneficiaries.   
Hypothesis 2.2: Comparing PIs versus no-ART therapy group, we hypothesize 
that the odds of developing T2DM after treatment with PIs is higher among the 
African American race compared to the odds of developing diabetes after 
treatment with PI use among the Caucasian beneficiaries. 
2.5.3 Aim 3: Economic burden of comorbid T2DM in beneficiaries with HIV/AIDS 
Aim 3.1: To assess the incremental healthcare cost associated with comorbid T2DM 
among beneficiaries with HIV/AIDS 
Although the economic burden of diabetes comorbidity in California Medicare is known, 
the current national economic burden of comorbid T2DM among HIV/AIDS positive 
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Medicare beneficiaries is unknown. We, therefore, hypothesize that total medical cost, 
total prescription cost, hospitalization cost, outpatient cost, total Medicare and OOP cost 
will increase for Medicare beneficiaries with comorbid T2DM compare to those without 
comorbid T2DM. 
Hypothesis 3.1: In HIV/AIDS positive Medicare beneficiaries with comorbid 
T2DM, total medical costs are higher compared to HIV/AIDS positive 
beneficiaries without comorbid T2DM 
Hypothesis 3.2: In HIV/AIDS positive Medicare beneficiaries with comorbid 
T2DM, total Medicare expenditures are higher compared to HIV/AIDS positive 
beneficiaries without T2DM 
Hypothesis 3.3: In HIV/AIDS positive Medicare beneficiaries with comorbid 
T2DM, total cost of hospitalization is higher compared to HIV/AIDS positive 
beneficiaries without comorbid T2DM 
Hypothesis 3.4: In HIV/AIDS positive Medicare beneficiaries with comorbid 
T2DM, total outpatient cost is higher compared to HIV/AIDS positive 
beneficiaries without comorbid T2DM 
Hypothesis 3.5: In HIV/AIDS positive Medicare beneficiaries with comorbid 






This chapter presents the conceptual framework based on Andersen’s behavioral 
model of health services, which was used to emphasize contextual and individual 
determinants of access to care. This chapter also presents discussions on how the 
Andersen’s model is adapted in this study to conceptualize the relationships between 
treatment with PIs and T2DM, racial/ethnic variation in risk and the economic burden of 
diabetes among individuals with HIV/AIDS.  
3.1 Andersen’s Behavioral Model  
Andersen’s behavioral model of health service utilization was first developed in 
the late 1960’s and has undergone several modifications over the years.137 This model is 
based on contextual and individual determinants of access to healthcare. Contextual 
determinants consist of the environment and circumstances impacting on health care 
access. Contextual determinants are aggregate level determinants ranging from small 
units (family, work group) to large units (country, community) unlike the individual 
determinants. The model suggests that each of the contextual and individual determinants 
constitute three major components of determinants which include: (1) predisposing 
factors that impacts health care access, (2) enabling factors that can facilitate or prevent 
the use of available health care and, (3) healthcare needs and other related conditions that 
inform healthcare use. 137 
 
61 
3.1.1  Individual characteristics domain 
 Predisposing characteristics at the individual level include age, gender, weight, 
height and genetic factors which may predict health care needs and predisposition to 
certain healthcare conditions which could motivate health care needs.138  Common 
chronic disease conditions such as T2DM cardiovascular diseases, age-related macular 
degeneration, depression, and cancer are not only age related and linked to family history 
but also has multifactorial and polygenetic etiology.139 Social factors consist of factors 
related to an individual’s status in the community and his/her ability to cope with 
immediate challenges and financial demands to addressing these challenges. These 
factors may include individual’s education level, race and ethnicity as well as occupation. 
Social factors may also include units of a society such as the family and friends as well as  
religious and social organizations that helps by improving societal cohesion and the 
social support needed to improve access to health care services.140 Furthermore, culture 
and belief systems could impact the individual’s perception of illness and treatment 
approaches.141 Belief systems may greatly impact their perception of needs for health 
care as well as use of health care services.141 
 Enabling factors to accessing health care ranges from having the resources to pay 
for healthcare services, presence of affordable health insurance in terms of effective 
prices for services, low cost sharing amount and deductibles. Social support from social 
organizations, religious organizations and social networks could be considered enabling 
factors from the perspective of emotional support, informational and affectionate support, 
and in some cases, financial support to obtain healthcare services.142 The need for health 
care, in general, is a function of both the patient’s perceived healthcare needs and 
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evaluated health care needs, which are based on objective, professional medical 
judgment. Professional judgment stems from the state of the art and sciences of medical 
practice, clinical guidelines and protocols, practice patterns, training, and competency of 
professional experts.140  These constitute individual characteristics factors as shown in 


























    
Figure 3.1: The Andersen’s behavioral model 
Source: Andersen RM, Davidson PL, Baumeister SE. Improving access to care in America. Changing the US health care system: 
key issues in health services policy and management 3a edición San Francisco: Jossey-Bass. 2007:3-31.
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3.1.2  Contextual characteristics domain 
 Collective individual demographic characteristics such as being elderly, married, 
female or male defines context characteristics and explains the way in which these 
characteristics may influence the availability of certain health care services when 
compared to a setting with a younger, single population.140 Social support at this level 
constitutes community or county-based support because it is available in the community 
where people live. This kind of support may have an impact on the local population’s 
health and access to care. Additional context predisposing characteristics may include 
spatial segregation and distribution of race and ethnicity within certain populations, 
educated versus uneducated people groups, employment rate and crime rates within a 
community.143 Common and diverse belief systems, culture, political ideologies and 
prevailing organizational values underpin the organization of healthcare, as well as how it 
is financed and made available to the community members.140  
 The major enabling factors in the context of characteristics or population-based 
factors that impact access to care consist largely of  governmental (legislative, executive 
or judicial) public health policies designed to enable aggregate access to health care for  the 
community or for a relevant community sub-group.140 The Affordable Care Act (ACA) 
represents a good example of a legislative public health policy which impacts access to 
care from the local to the national level. Other policies may include private and internal 
organizational policies that may enable access to aggregate care. Some may include 
managed care organization policies concerning product pricing, marketing or product lines 
and quality assessment policies from the National Committee for Quality Assurance 
(NCQA).140 From the perspective of contextual enabling factors, financial policies,  in 
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addition to health policies ,represent available resources to pay for health care. Those 
policies also consider the communities’ per capita income and wealth and incentives for 
payment of health care services. In addition they consider provider’s methods of 
compensation that would sustain a reasonable cost of health care and health insurance 
coverage in the community.140 Availability and distribution of health facilities, 
providers/personnel ratio to patients, physician and hospital bed ratios and the way in 
which the facilities are structured for healthcare delivery represents organizational enabling 
factors that impact on access to care in the community.  
 Need characteristics in the context perspective constitutes the environment where 
people live and how it predicts their perceived or evaluated health needs. The model 
suggests that physical environment, such as quality of housing, water, and air, could 
suggest how healthy the environment might be and the prevailing health needs.140 Death 
and injury rates as well as environmental causative factors could also suggest the 
community health status and aggregate health care needs.140 High mortality or morbidity 
rates may be linked to specific environmental factor such as road accidents, disease 
epidemics, infant mortality and a high prevalence of chronic conditions. These individual 
and context characteristics typically influence health behavior and the prevailing health 
outcomes.  
3.1.3  Health behaviors 
 Health behaviors are those health-related activities and habits that individuals 
exhibit towards their health care. They may include healthy living such as diet and 
nutrition, exercise, alcohol and drug abuse, health consciousness and adherence to 
medical advice and medication use or non-compliance. Good health behavior is a 
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function of how well the provider interacts with a patient during the care process. 
According to Donabedian, the process of medical care constitutes an effective interaction 
between the provider and the patient that would lead to the patient exhibiting essential 
behavior and habits that will benefit their health. This  includes adherence to care, 
compliance with medications, and dieting.144 A quality care process could be determined 
by measures such as patient and physician communication, provider counselling and 
education, prescription patterns, ordering of necessary diagnostic tests, and relevant vital 
signs examinations. Personal health service use is an essential component of healthy 
behavior. Based on the model, the contextual predisposition, enabling, and need factors 
occurring through the individual characteristics predicts health services use.140 The use of 
health services may occur as inpatient care, outpatient care, dental care or ambulatory. 
The type of care is determined by predisposing factors such as age, gender, genetic 
dispositions, enabling factors such as availability of facilities, insurance and financial 
resources to afford care and finally the perceived and evaluated healthcare need such as 
pain, diagnosis and laboratory results. For instance, a patients perceived need for dental 
care may result from a tooth ache, pain, bleeding gums, social conditions, health beliefs, 
and/or enabling resources.140 The severity of condition of the patient’s  health based on 
evaluated need would predict more intensive care at the inpatient level rather than less 
intensive care at the outpatient level.  
The Andersen’s behavioral model suggest that contextual characteristics can 





For instance, the Medicaid expansion policy leads to increased insurance rates for low-
income children and members of society, thereby resulting in increased health services 
use.  
3.1.4  Outcomes 
 Patients’ health behavior, personal health services, individual characteristics, and 
global context environment influence their health outcome or perceived health status. 
Based on this model, the purpose of personal healthcare use is to reduce the perceived or 
evaluated health care needs which is measured as health status improvement from the 
patient’s perspective and the physician’s evaluated perspective.140 A patient’s perceived 
health outcomes may include lack of pain after treatment, improvement in daily 
functionality, and improved general well-being.  Comparatively, evaluated health status 
includes laboratory test results and analysis of biomarkers of disease prognosis. The 
patient’s perceived outcomes can also be measured as their satisfaction of the health care 
services, they received, which could be measured in terms of a patient’s rating of the 
provider on patient communication, waiting time, hospitalization days, and frequency of 
re-admissions. Whether or a not a patient switches care plans could also be used as a 
measure for satisfaction from the health insurance perspectives.145  
With the increasing need and interest in patient-centered care, Patient Reported 
Outcomes (PRO) is increasingly being used to measure overall treatment benefits from 
the perspective of the patient. Typically, PROs are used for the purpose of documenting 
patient experiences with treatment in terms of side effects, the improvement of 
symptoms, and quality of life.146 Thus, incorporating quality of life in the Andersen’s 
behavioral model would better explain a patient’s perceived reduction in quality of life 
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related to their healthcare needs.140 Quality of life measures is one of the seven constructs 
used in patient reported outcome instruments (PRO) and it is the most frequently used of 
the PRO measurement constructs.  Several PRO tools are constructs such as Functional 
Assessment of Cancer Therapy—Breas (FACT-B), European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire—Core 30, EuroQol 5-
Dimensions and EORTC QLQ—Breast Cancer Module.146 
3.2  Adapted Model 
This model is applied in this dissertation to explain the association between use of 
PIs and the odds of developing T2DM among HIV positive Medicare beneficiaries 
continuously enrolled in Medicare Part A, Part B and Part D, to explain racial variations 
in the  development of T2DM, and additional costs of healthcare use due to comorbid 
T2DM . Figure 3.2 represents the conceptual framework adapted from Andersen’s 
behavioral model for this dissertation. The adapted model consists of the individual and 
contextual characteristics and outcomes.  
Environmental or regional factors are important predisposing factors to certain 
disease conditions which predict regional healthcare use and health outcomes. For 
instance, regional disparity in the prevalence of T2DM can be seen in that it is 
disproportionately distributed in the Southern regions of the US, also referred to as the 
‘diabetes belt’.147 Regional disparities in T2DM prevalence is a function of 
disproportionate distribution of risk factors of T2DM, infrastructures and facilities that 
enable a healthy life-style.147 A recent study suggested that community-level correlates of 




The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 
which established the Medicare Part D prescription drug program on January 1, 2006 
represents context based enabling factors through the Low-Income Subsidy (LIS) 
program, which is offered to Medicare beneficiaries. With this legislative Act, 
beneficiaries can access expensive HIV/AIDS medication through Medicare Part D and 
additional cost sharing assistance for those eligible for LIS. 
Individual predisposing characteristics include demographic factors such as age 
and gender which are known to be associated with health care use. Race/ethnicity is a 
relevant social factor because of its association with T2DM and HIV/AIDS, and thus 
predicts access to care and health outcomes for individuals with these conditions. The 
epidemiology of T2DM and HIV/AIDS varies across race/ethnicity among Medicare 
beneficiaries.12,65 Individual enabling factors is constituted of their enrollment in 
Medicare Part A and Part B insurance plans and dual eligibility in both Medicare and 
Medicaid which impacts health care use. Another individual enabling factors for health 
care access include enrollment in both Medicare and Medicaid, otherwise known as dual 
eligibility. Dual eligible beneficiaries receive extended and more comprehensive 
coverage with cost sharing assistance since Medicaid covers services which Medicare 
does not cover and vice versa. Also, Medicaid provides supplemental coverage that helps 
to cover premiums and cost sharing for low-income dual beneficiaries.49 Individual need 
for healthcare is constituted of the patient’s perceived symptoms and evaluated need for 
HIV/AIDS and diabetes treatment based on diagnostic tests and clinical assessment. 
In the adapted model, Medicare beneficiaries diagnosed of HIV/AIDS or diabetes 
are either hospitalized or treated on an outpatient basis and receives medication through 
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Medicare Part D. The health behavior domain also includes study outcomes, which in this 
dissertation is the diagnosis of diabetes following treatment with PIs as an adverse drug 
event. This dissertation aims to determine the odds of developing T2DM among 
HIV/AIDS patients treated with PIs compare to those treated with other medications. 
Based on the physiological process of HIV treatment and the risk of diabetes, use of PIs 
is associated with T2DM through impact on insulin sensitivity, resulting in insulin 
resistance, and consequently T2DM. Secondary outcomes in the adapted models include 
race/ethnicity variation in the development of T2DM and a measure of additional cost of 
care due to T2DM comorbidities among beneficiaries with HIV/AIDS. The presence of 
diabetes among HIV/AIDS positive Medicare beneficiaries may constitute additional 
healthcare utilization and a corresponding incremental economic burden to Medicare, 























This section discussed various aspects of research methodology including data 
sources, the study design, the study population, definition of case and control groups, 
variables, and statistical analysis. 
4.1 Data Source 
A random sample of national Medicare administrative claims data from the years 
2013 to 2017 was used to analyze Medicare population with HIV/AIDS. Medicare is the 
US federal health insurance program established in 1965 to provide healthcare coverage 
for Americans aged 65 years or older, regardless of income level or medical history.50 
Medicare coverage was expanded in 1972 to provide coverage for individuals under 65 
years of age with long-term disability and who receive Social Security or Railroad 
Retirement Board benefits, and individuals with End Stage Renal Disease.50,149 Currently, 
Medicare provides health coverage to 60 million people who are disabled or elderly. This 
coverages provides basic health services such as inpatient care, physician visits, 
prescription drugs, preventive services, skilled nursing facilities, home health care, and 
hospice care.50 Approximately 84 % of beneficiaries are eligible for  Medicare benefits 
because of age, while 16 % are younger beneficiaries who receive benefits because of 
disabilities such as end-stage renal failure.12  
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Medicare health insurance constitutes Part A (hospital insurance), Part B (medical 
insurance), Part C (Medicare Advantage) and Part D coverage types. Parts A, B, and D 
are available through traditional Medicare Fee-For-Service (FFS) plans. Part A insurance 
type is a plan that provides coverage for care received in inpatient settings, SNF, 
hospices, or home health care settings. Part B, also known as medical insurance, covers 
physician services such as injections, procedures, diagnostic tests, other outpatient care, 
DMEs, preventive services, and some home health care regardless of whether care was 
received in an inpatient or outpatient setting. Almost all Medicare beneficiaries are 
enrolled in either of Part A, Part B, or both.150 In 2006, Medicare offered  Part D, 
prescription drug coverage, to eligible beneficiaries. Beneficiaries enrolled in the Part D 
plan receive benefits that help pay for outpatient prescription drug costs, which is 
essential for low income patients with especially expensive drug costs.50 Plan D coverage 
is voluntary and occurs through contractual arrangements between Medicare and private 
plans such as PDPs and MA-PDs.50 The Part D plan also provides additional financial 
benefits for enrollees with low incomes and modest assets. In 2018, 25%  of the over 43 
million Medicare beneficiaries who were enrolled in either a PDP or MA-PD received a 
low-income subside.50  
Typically, Medicare data include enrollment information of each beneficiary, 
including information such as enrollment eligibility, demographic characteristics and 
claims information. This information captures nearly all aspect of healthcare services 
throughout all levels of healthcare.151. For services provided to Medicare beneficiaries, 
physicians and other healthcare providers submit claims to the Center for Medicare and 
Medicaid Services (CMS). The CMS then review and process the claims for 
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reimbursement to the healthcare providers. From the reviewed claims, the CMS generates 
Standard Analytical Files (SAF) annually. Typically, the SAF contains final researchers 
encrypted claims for Parts A and B services and Part D prescription drugs for services 
received in the hospital, physician offices, hospice, and SNFs through December 31 of 
the latest available calendar year.149 SAF also contains beneficiary’s enrollment and 
demographic information such as gender, age and race/ethnicity as well as provider 
characteristics such as the provider’s unique number, the physician’s clinical specialty, 
the national physician number and geographic information for facilities.149 This study 
uses a national random sample of 1 million Medicare beneficiaries. It is suitable for this 
study because it covers nearly all health care utilizations for each eligible beneficiary 
across all levels of healthcare services provision. Specifically, it is rich in information 
such as demographic data, claims and costs, clinical and diagnosis information, 
prescription drug use and costs, all payments sources, along with mortality and discharge 
information.  
4.2 Study Design 
In study aim 1 and 2, we performed a nested case-control study of Medicare 
beneficiaries living with HIV/AIDS to analyze the association between treatment with PI 
and development of T2DM. (Figure 4.1.) In study aim 3, a pooled cross-sectional study 
design was used to analyze the economic burden of comorbid T2DM among beneficiaries 
diagnosed with HIV/AIDS for a pooled period of 2013 - 2017. The study protocol was 
approved by the University of South Carolina Institutional Review Board (IRB) as 



































Figure 4.1: Study design sketch for study aim 1 and 2
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4.3  Study Population  
In study aims1 and 2, we identified beneficiaries with diagnosis of HIV/AIDS 
based on the International Classification of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM) code for HIV/AIDS (042-044, 079.53, V08)152 and/or International 
Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code for 
HIV/AIDS (B20.xx, Z21)153 between 2013 to 2017. Six months washout period starting 
from January 1 to July 1, 2013 was applied to determine new T2DM diagnosis. (Figure 
4.1.) The cohort entry date was set as the date after the washout period (July 1, 2013). 
The study included only beneficiaries that were continuously enrolled in Medicare Part A 
and B plans throughout the analytical time frame to ensure complete diagnosis 
information and medical records. Medicare beneficiaries enrolled in HMOs were also 
excluded.  
In study aim 3, the study sample includes Medicare beneficiaries who have been 
diagnosed with HIV/AIDS based on the ICD-9-CM code for HIV/AIDS (042-044, 
079.53, V08)152 and/or ICD-10-CM code (B20.xx, Z21).153 To ensure a complete 
diagnosis and medical records, only beneficiaries that were continuously enrolled in 
Medicare Part A and B throughout the analytical time frame were included. Medicare 
beneficiaries enrolled in HMOs were excluded. The study excluded Medicare 
beneficiaries with End Stage Renal Disease (ESRD) because healthcare expenditure for 
beneficiaries with disabilities such as ESRD is more than twice as much for people with 
persistent or chronic disabilities than for those with temporary or no disability.154 
Excluding these patients would help prevent extreme or outlying cost observations and its 
possible impact on regression estimate.  
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4.4  Case and Control Groups 
In study aim 1 and 2, we identified cases as HIV/AIDS positive beneficiaries with 
diagnosis of T2DM based on the ICD-9-CM code (250.xx) or  ICD-10-CM code 
(E11.xxx).155 The first diagnosis of T2DM was set as the index date. Control group 
included HIV/AIDS positive beneficiaries who had no record of a T2DM diagnosis. 
(Figure 4.1.)   
4.5 Measurements 
4.5.1 Dependent and independent variables  
Medication exposure variable for this study were classified into (1) PI treatment 
defined as cumulative treatment with PIs (≥ 60-day supply), (2) non-PI treatment defined 
as cumulative treatment with PIs (≤ 60-day supply); and or treatment with other ARTs; 
and; (3) no-ART treatment defined as beneficiaries with no ART prescriptions. 
Measurement of PI use in this study is a modified form of measurement approach used in 
Tripathi et al 108 (Table 4.1). Tripathi et al calculated exposure to ART based on 30-day 
exposure while in this study, we calculated PI use based on a 60-day cumulative use. 
Treatments were based on the most recent prescription date preceding the index date or 
December 31, 2017 whichever came first. Drug use information was extracted from the 
prescription drug event file component of the Medicare data using the generic name 
variable. Two therapy comparison groups were created from the medication exposure 
variables as follows: (1) cumulative treatment with PI (≥ 60 days) versus cumulative 
treatment (≤ 60-day) and or treatment with other ARTs and (2) cumulative treatment with 
PI (≥ 60 days) versus no treatment with ART. The outcome of interest for study aims 1 
 
78 
and 2 was the diagnosis of T2DM determined based on ICD-9-CM code (250.xx) or ICD-
10-CM code (E11.xxx).155 T2DM diagnosis variable was categorized into two level 
binary variables- T2DM= 1 for positive diagnoses and T2DM=0 for negative T2DM 
diagnoses.  
In study aim 3, the main predictor variable was comorbid T2DM assessed based 
on ICD-9-CM code (250.xx) or  ICD-10-CM code (E11.xx)155. The predictor variable 
was categorized into two level binary variable- T2DM= 1 for positive diagnoses and 
T2DM=0 for negative T2DM diagnoses. The outcomes measures in study aim 3 were six 
relevant measures of economic burden such as the costs of health care services received- 
(1) total hospitalization cost, (2) total outpatient cost, (3) total prescription costs, (4) total 
Medicare costs, (5) total OOP  and (6) total medical costs. The Assessment of the 
economic burden based on these costs ensures availability of evidence of economic 
burden across all facets of health care service types -inpatient, outpatient and OOP.  
The Medicare inpatient and outpatient analytical file consist of cost variables 
which include: ‘claim payment amount’, ‘claim pass thru per diem amount’, ‘claim 
utilization day count’, ‘NCH beneficiary inpatient deductible amount’, ‘NCH beneficiary 
part a coinsurance liability amount’, ‘NCH beneficiary blood deductible liability amount’ 
and ‘NCH primary payer claim paid amount’.156 Total Medicare cost was calculated by 
summing up the ‘claim payment amount’ and the product of the ‘claim pass thru per diem 
amount variable’ and the ‘claim utilization day count variable’ in the inpatient and 
outpatient files and calculating average annual Medicare cost per patient.156 Total OOP 
cost was calculated by summing up the NCH beneficiary inpatient deductible amount 
variable, NCH beneficiary Part A coinsurance liability amount variable, and the NCH 
 
79 
beneficiary blood deductible liability amount variable from both the inpatient and 
outpatient files and calculating average annual OOP per patient.156 Total inpatient costs 
were calculated by summing up the total Medicare inpatient payments + OOP  inpatient 
costs + NCH primary payer claim paid amount in the inpatient file and calculating 
average annual inpatient cost per patient.  Total outpatient cost was calculated by 
summing up the total Medicare outpatient costs + OOP  outpatient costs + NCH primary 
payer claim paid amount in the outpatient file and calculating average annual cost per 
patient.156 Total prescription drug costs were determined using the gross drug cost 
variable- ‘TOT_RX_CST_AMT’. Total medial costs were calculated by summing the 
total OOP costs, total Medicare payments, and the total prescription cost and calculating 















Table 4.1: List of peer reviewed studies and measurement approach for ART exposure  
Author 
(Years) 




Risk of diabetes mellitus 
in persons with and 
without HIV: a Danish 
nationwide population-
based cohort study 
Cohort Study Patient initiated on a 
specific ART regimen 
was considered exposed 
to such regimen for the 
rest of the observation 
period independent of 




Dyslipidemia and fasting 
glucose impairment 
among HIV patients 
three years after the first 
antiretroviral regimen in 




Only patients on their 
first ART regimen were 
studied. In case of 
change or 
discontinuation of initial 
ART regimen, ART 
regimen used for at least 




Incidence of diabetes 
mellitus in a population‐
based cohort of HIV‐
infected and non‐HIV‐
infected persons: the 
impact of clinical and 





combination ARTs was 





Higher Risk of 
Hyperglycemia in HIV-
Infected Patients Treated 




Exposure to ART was 
based on unmodified 
use of any ART regimen 
for a period of 12 
month. 
 
Estimating the economic burden based on health expenditures over the years 
requires an adjustment for inflation to dollars of equivalent purchasing power because 
costs incurred this year for instance is not the same as the costs incurred over the previous 
years for the same items or services received. Prices for health care changes annually and 
faster than overall price inflation.  Thus, selecting indexes that are specific for medical 
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expenditures and also account for changes in healthcare prices is paramount for correctly 
estimating health care expenditure.159  
Consequently, the Personal Health Care Index (PHC) and the Personal 
Consumption Expenditure Health Indexes (PCE) are recommended over the medical 
component of the consumer price index (CPI-M) and the GDP price index for medical 
care by the Medical Expenditure Panel Survey (MEPS).160 While the PHC and the PCE 
indexes are more appropriate for estimating personal health care expenses than both the 
GDP price index and the CPI-M, CPI-M is the most appropriate for pooling OOP.  
Conversely, the  GDP price index is the least appropriate in  medical expenditure 
research.160 This is due to the fact that the GDP price index includes expenditures from 
medical and public health research which are not useful in health care services utilization 
and cost estimation.160 The PHC index was constructed based on the components of the 
CPI-M and Producer Price Index (PPI) by the CMS office of the Actuary, and the PCE 
was constructed from the CPI and PPI by the Bureau of Economic Analysis (BEA).160 
In this study, PHC was used to adjust for inflation to 2017 dollar for inpatient and 
outpatient costs while CPI-M was used for OOP costs. (Table 4.2) The following 
equation represents the formula used to obtain the 2017 U.S. dollar values. 
























Source: Using Appropriate Price Indices for Analyses of Health Care Expenditures or Income Across  
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2013 102.2 1.052 100.1 1.000 425.1 1.118 
2014 103.5 1.039 100.6 0.995 435.3 1.092 
2015 104.5 1.029 99.5 1.006 446.8 1.064 
2016 105.7 1.017 99.7 1.004 463.7 1.025 
2017 107.5 1.000 100.1 1.000 475.3 1.00 
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4.5.2   Potential confounders 
Based on the conceptual framework as adapted from the Andersen’s behavioral model 
of health services utilization, potential confounding factors included were predisposing 
characteristics, enabling factors and healthcare needs. Specifically, covariates included in the 
multivariate regressions were predisposing characteristics (age, gender and race), enabling 
factors (regions, dual eligibility status) healthcare needs (Charlson Comorbidity Index (CCI), 
and Chronic Hepatitis C and B virus infections (HCV & HBV). Covariates were measured 
from Medicare beneficiary summary files and claims. This study used CCI as a measure of 
comorbidities which is widely used to measure the number of chronic disease comorbidities. 
It is calculated based on ICD-9-CM or ICD-10-CM codes identified in the Medicare database. 
Diabetes and HIV/AIDS were excluded from the CCI calculation. HBV/HCV was determined 
using HBV infection specific ICD-9-CM codes 0702, 07020, 07021, 07022, 07023, 07030, 
07031, 07032, 07033,VO261161 or ICD-10-CM codes: B181, B1910, B189 162 and HCV 
infection specific ICD-9-CM codes: 07054, 07044, 07070, 0707, 07071,07041, VO262, 
07051161 or ICD-10-CM codes: B182, B1920 and B189.163 
4.6 Propensity Score Matching  
Differences in subject’s baseline demographic and clinical characteristics may have 
influenced assignment into therapy groups, and this consequently may impact the result of 
this study. To minimize these differences in characteristics and selection biases, PS matching 
was performed for each of the therapy group pairs (1) PI use versus non-PI use and (2) PI use 
versus no-ART.164 The PS matching approach generates a pseudo-randomized population 
where beneficiaries are similar in terms of their baseline characteristics and differ only by 




Patient-specific propensity scores were estimated by fitting a logistics regression 
model predicting the odds of being prescribed PIs instead of (1) non-PIs and (2) no-ARTs, 
including covariates such as age, gender, sex, race, HCV/HBV, regions and dual eligibility. 
PS-matched study sample was created by matching on the propensity scores based on a 1:1 
greedy matching algorithm. CCI characteristics were excluded in the PS matching to enable 
matching of at least 40% of the complete sample. Using 0.3 cut-off, units were matched only 
if the difference in the logits of the propensity scores for pairs of units from the two groups is 
less than or equal to 0.3 times the pooled estimate of the standard deviation. Residual 
unmatched beneficiaries were excluded. Balance and comparability of baseline characteristics 
across therapy groups were evaluated using chi-square test. P-value greater than 0.05 was 
considered a good balance in baseline characteristics. This study leveraged a case-control 
study with a PS matching methodology employed by Nussbaum et al. 165  In their study, they 
used PS matching approach to generate matched therapy groups- preoperative radiotherapy 
versus no radiotherapy and (2) postoperative therapy versus no radiotherapy and compared 
overall patient’s survival between the matched groups.165  
4.7 Statistical Analysis 
In study aims 1 and 2, we describe baseline characteristics of unmatched and PS 
matched eligible beneficiaries using chi-square test to compare covariate’s balance between 
both therapy group pairs. Unadjusted logistic regression was performed to determine crude 
associations between PI use and the odds of developing T2DM for each therapy group pair, 
and unadjusted association within race sub-groups. In study aim 3, baseline covariates were 
compared between history of T2DM status using chi-square for categorical covariates. 
Independent two-group tests were performed to compare different costs between beneficiaries 
with a history of T2DM while unadjusted GLM analysis was performed to determine 
unadjusted impact of patients with a previous history of T2DM on different healthcare costs. 
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Multivariate logistic regressions were performed to determine the odds of developing T2DM 
and racial variations in the odds of developing T2DM. A multivariate Generalized Linear 
Model (GLM) was performed to determine the impact of comorbid T2DM on different health 
care costs. All data analysis was carried out using SAS version 9.4 (SAS Institute, Cary, NC).  
4.7.1 Bivariate analysis 
Therapy group pairs (PI versus non-PIs and PI versus no-ART) in both matched and 
complete datasets were compared using chi-square to determine balance across covariates 
(age, gender and race, regions, dual eligibility status, HBV & HCV and CCI). For continuous 
variables such as cost domains, an independent two-group t-test was used to determine mean 
cost differences between beneficiaries with T2DM compare to those without T2DM. 
Unadjusted regression was performed to determine the association between treatment with PI 
and the odds of developing T2DM, racial variation in odds of developing T2DM and the 
effect of comorbid T2DM on different healthcare costs. 
 Unadjusted logistics regression was performed for each therapy group pair as in 
Formula 4.1 to determine unadjusted odds of developing T2DM.  
In (odds that Y=1) = â0 + â1 (Therapy group) + μi       (Formula 4.1) 
 
 Y is a dummy variable indicator for T2DM diagnosis 
▪ 0: Negative T2DM diagnosis 
▪ 1: Positive T2DM diagnosis 
  Therapy groups 
▪ PI versus non-PI pair 
▪ 0: Non-PI  
▪ 1: Pi  
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▪ PI versus no-ART 
▪ 0: No-ART  
▪ 1: PI  
In Formula 4.1, ‘â1’ was the coefficient for the predictor of interest. The odds ratio comparing 
the odds of developing T2DM between therapy groups pair was measured as ‘exp(â1)’.  
Unadjusted logistics regression was performed for each therapy group pairs to 
determine odds of developing T2DM using Caucasian and African American sub-groups as in 
Formula 4.2 
In (odds that Y=1) = â0 + â1 (Therapy group [race-subgroup]) + μi      (Formula 4.2) 
 Y is a dummy variable indicator for T2DM diagnosis 
▪ 0: Negative T2DM diagnosis 
▪ 1: Positive T2DM diagnosis 
  Therapy groups 
▪ PI versus non-PI pair 
▪ 0: Non-PI  
▪ 1: Pi  
▪ PI versus no-ART 
▪ 0: No-ART  
▪ 1: PI  
In both race sub-group bivariate logistic regression model, ‘â1’ represents the coefficient of 
predictor of interest. The odds ratio comparing the odds of developing T2DM with respect to 
the compared therapy group pairs within Caucasian or African American subgroups was 
measured as ‘exp(â1)’.   
Unadjusted GLM regression was performed in Formula 4.3 to determine unadjusted 
impact of history of T2DM on different health care costs: (1) total Medicare costs, (2) total 
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prescription costs, (3) total OOP , (4) total healthcare costs, (5) total hospitalization cost and 
(6) total outpatient cost. 
 
Log (E (Y)) = â0 + â1 (Comorbid T2DM) + μi   (Formula 4.3) 
 
 Y is a continuous variable representing each of the cost domains: Total cost of 
hospitalization, total outpatient costs, total Medicare costs, total prescription drug 
costs, total OOP and total healthcare costs. 
 
  Comorbid T2DM is dummy variable indicating comorbid T2DM 
▪ 0: No diabetes diagnosis 
▪ 1: Diabetes diagnosis 
In each bivariate GLM regression, ‘â1’ represents the coefficient of predictor of interest 
which is the estimate of percentage changes in cost between group with comorbid T2DM and 
group without comorbid T2DM measured as ‘[exp(â1-1) *100].  
 
4.7.2  Multivariate analysis  
4.6.3.1 Aim 1: Treatment with PIs and odds of developing T2DM 
After generating two PS matched data sets for - (1) PI versus non-PI and (2) PI versus 
no-ART, multivariate logistic regression was performed as in Formula 4.4 to determine the 
odds of developing T2DM for each comparison pairs.  
In (odds that Y=1) = â0 + â1 (Therapy group) + â2 (Predisposing characteristics) + â3 
(Enabling factors) + â4 (Healthcare need) + μi    (Formula 4.4) 
 
 Y is a dummy variable indicator for T2DM diagnosis 
▪ 0: Negative T2DM diagnosis 
▪ 1: Positive T2DM diagnosis 
  Therapy groups 
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▪ PI versus non-PI pair 
▪ 0: Non-PI  
▪ 1: Pi  
▪ PI versus no-ART 
▪ 0: No-ART  
▪ 1: PI  
 Predisposing characteristics includes various demographic variables 
▪ Age group: 1: 18-34 (Reference), 2: 35-44, 3: 45-54, 4: 55-64 and 5:  > 64 
▪ Gender: 1: Male, and 2: Female (Reference) 
▪ Race: 1: Caucasian (Reference), 2: African Americans and 3: Others 
 Enabling factors includes region and residence where Medicare beneficiaries leave 
▪ Dual Eligibility Status: 0: No and 1: Yes 
▪ Regions: 1: West, 2: South, 3: Midwest and 4: Northeast 
 Healthcare needs: This includes clinical characteristics variables 
▪ Charlson Comorbidity Index (CCI): ≤ 1, 2 and 3+ 
▪ Hepatitis C & B virus infection (HCV& HBV): positive HCV or HBV 
diagnosis=1 and negative HCV and HBV diagnosis=0. 
In Formula 4.4, ‘â1’ was the coefficient for the predictor of interest. The odds ratio comparing 
the odds of developing T2DM between therapy groups pairs was measured as ‘exp(â1)’.  
4.6.2.2 Aim 2: Racial disparity in odds of developing T2DM following treatment with PIs 
Using the PS matched data sets for - (1) PI versus non-PI comparison and (2) PI 
versus no-ART therapy, an analysis of Caucasian and African American race sub-groups was 
performed using multivariate logistic regression model to assess variations in the odds of 
developing T2DM for both therapy pairs within Caucasian and African American subgroups. 
In Formula 4.5, a multivariate race sub-group analysis did not include race variables since 
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race sub-groups were being assessed. A multivariate logistic model for each therapy group 
pair (in Formula 4.5) was performed separately for Caucasian and African American sub-
groups. 
In (odds that Y=1) = â0 + â1 (Therapy group [race sub-group]) + â2 (Predisposing 
characteristics) + â3 (Enabling factors) + â4 (Healthcare need) + μi (Formula 4.5) 
 
 Y is a dummy variable indicator for diabetes diagnosis 
▪ 0: Negative T2DM diagnosis 
▪ 1: Positive T2DM diagnosis 
  Therapy groups 
▪ PI versus non-PIs therapy group pair 
▪ 0: Non-PI 
▪ 1: PI 
▪ PI versus no-ART therapy group pair 
▪ 0: No-ART  
▪ 1: PI  
 Predisposing characteristics includes various demographic variables 
▪ Age group: 1: 18-34 (Reference), 2: 35-44, 3: 45-54, 4: 55-64 and 5:  > 64 
▪ Gender: 1: Male, and 2: Female (Reference) 
 Enabling factors includes region and residence where Medicare beneficiaries leave 
▪ Regions: 1: West, 2: South, 3: Midwest and 4: Northeast 
▪ Dual Eligibility Status: 0: No and 1: Yes 
 Healthcare needs: This includes clinical characteristics variables 
▪ Charlson Comorbidity Index (CCI): ≤ 1, 2 and 3+ 
▪ Hepatitis C & B virus infection (HCV & HBV): positive HCV or HBV 
diagnosis=1 and negative HCV and HBV diagnosis=0. 
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In each of the race sub-group multivariate regression, ‘â1’ represents the coefficient of 
the predictor of interest. The odds ratio comparing the odds of developing T2DM between the 
compared therapy group pairs within Caucasian or African American subgroups was 
measured as ‘exp(â1)’.  
4.6.2.3 Aim 3: Effects of comorbid T2DM on healthcare costs 
In aim 3, GLM with log link and gamma distribution was used to assess the economic 
burden of comorbid T2DM. Cost and utilization data are often skewed, gamma distributed, 
and violates independent observation assumption. These characteristics violate Ordinary Least 
Squares regression (OLS)-normality and homoscedasticity assumptions given that it is often 
right-hand skewed with significant heteroskedasticity.166,167 The independent observation 
assumption is commonly violated by cost data, given that multiple individuals using the same 
healthcare services may incur similar total health care costs.  
Gamma GLM is suitable for modeling positively skewed data, non-negative data 
with variances not proportional to the square of the means and of which there are certain 
forms of heteroscedasticity.168  In addition, it has been demonstrated in Amal Saki et al. 
that gamma GLM is a good model for estimating the population mean of healthcare cost 
data.169 Although, non-normally distributed data could be normalized using 
transformations, the back transformation to the original scale may generate a biased 
estimate if the error term has inconsistent variance which is often the case with count 
data.170 Even if back transformation is considered a valid approach, interpretation of 
results is often a concern because estimates of a transformed scale cannot generate 
inference to healthcare mean cost.171 Given the above concerns, GLM modeling is the 
most appropriate model to use in cost estimation because it directly models costs in its 
original scale, corrects possible skewed distribution of cost data, and generates estimates 
that can be inferred to healthcare costs.  
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To use a gamma GLM for this study, the decision on what link and distribution 
would be used in analysis of cost data is made based on statistical tests. Box-Cox 
procedure was performed to generate possible links that could be used for the GLM 
modeling as shown in Table 4.3 below.172 To determine the distribution, the modified 
Park test procedure on raw-scaled residuals was used to select the distribution family to be 
used based on the relationship between variance and mean as shown in Table 4.4 
below.172 At lambda = 0, the mean and variance relationship are orthogonal, thus Gaussian 
distributional assumption is considered. At lambda =1, mean and variance relationship are 
proportional, thus Poisson-like distribution assumption is considered. At lambda = 2, 
mean and variance relationship is quadratic and thus Gamma distributional assumption is 
considered. At lambda = 3, the mean and variance relationship are cubic thus, inverse 
Gaussian distributional assumption is considered.172 Based on the modified Park test 







































Table 4.4: Distribution options for GLM modeling 
Lambda Mean & variance relationship Distribution 
0 Orthogonal Gaussian NLLS 
1 Proportional Poisson 
2 Quadratic Gamma 
3 Cubic Inverse Gaussian 
 
The GLM in Formula 4.6 was used to determine the economic burden of comorbid 
T2DM among HIV/AIDS positive Medicare beneficiaries. This was repeated for each of 
the six cost domains: (1) total Medicare costs, (2) total prescription costs, (3) total OOP, 
(4) total medical costs, (5) total hospitalization cost and (6) total outpatient cost. 
Log (E (Y)) = â0 + â1 (comorbid T2DM) + â2 (Predisposing characteristics) + â3 (Enabling 
factors) + â4 (Healthcare need) + â5 (Therapy group) + μi 
 
(Formula 4.6) 
 Y is a continuous variable representing each of the cost domains: Total cost of 
hospitalization, total outpatient costs, total Medicare costs, total prescription drug 
costs, total OOP and total healthcare costs. 
  Comorbid T2DM is dummy variable indicating comorbid T2DM 
▪ 0: No diabetes diagnosis 
▪ 1: Diabetes diagnosis 
 Therapy groups 
▪ PI versus non-PIs therapy group pair 
▪ 0: Non-PI 
▪ 1: PI 
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 Predisposing characteristics includes various demographic variables 
▪ Age group: 1: 18-35 (Reference), 2: 35-44, 3: 45-54, 4: 55-64 and 5:  > 64 
▪ Gender: 1: Male, and 2: Female (Reference) 
▪ Race: 1: Caucasian (Reference), 2: African Americans and 3: Others 
 Enabling factors includes region and residence where Medicare beneficiaries leave 
▪ Regions: 1: West, 2: South, 3: Midwest and 4: Northeast 
▪ Dual Eligibility Status: 0: No and 1: Yes 
 Healthcare needs: This includes clinical characteristics variables 
▪ Charlson Comorbidity Index (CCI): ≤ 1, 2 and 3+ 
▪ Hepatitis C & B virus infection (HCV & HBV): positive HCV or HBV 
diagnosis=1 and negative HCV and HBV diagnosis=0. 
 
In each multivariate GML regression, ‘â1’ represents the coefficient of a predictor of interest, 
which is the estimate of percentage changes in cost between groups with a comorbid T2DM 
and groups without a comorbid T2DM measured as ‘exp(â1-1) *100’.  
4.8  Sensitivity Analysis  
We performed sensitivity analysis to evaluate the robustness of the results in aim 1 
and 2 to possible analytical perturbations resulting from the matching approach used. 
Specifically, PS matching approach includes only the matched subjects in the final matched 
dataset and exclude unmatched subjects, which could impact the main results. To evaluate the 
sensitivity of these exclusions on the main results, logistic regressions were re-fitted using the 
inverse probability-of-treatment weighting (IPTW) (instead of matching) which is a type of 
PS analytical methods that uses the full sample in the analysis. 
IPTW uses PSs to form weights and create a pseudo-population in which the baseline 
characteristics and assignment to PI treatment are independent of each other (mimicking the 
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randomization setting). The term pseudo-population assumes that the weighted group could 
have been generated from a population in which there was no confounding.173 IPTW is 
performed by estimating each individual’s probability (PS) to be assigned to their respective 
treatment groups (either PI or non-PI) based on observed characteristics, and then generate 
weight by the inverse of this estimated PS. Beneficiaries treated with PIs are assigned a 
weight of a 1/p(Z=1|X), and beneficiaries treated with the control (non-Pi or no-ART) are 
assigned a weight of 1/(1-p(Z=1|X), where Z is a binary treatment indicator (PI-status) and X 
is a vector of observed baseline characteristics.173 The generated weight were stabilized to 
avoid extreme weights which may results in an analysis that is dependent on a few individuals 
with extreme weights.173  
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                                                      CHAPTER 5
RESULTS 
The results of this dissertation are shown in three major sections in this chapter. 
The first section includes the sample selection flow chart (used for study aim 1 and 2), the 
descriptive and multivariate results for study aim 1. Section two contains the descriptive 
and multivariate results of aim 2. Section three includes the sample selection flow chart, 
descriptive and multivariate results.  
5. 1 Treatment with PI and Development of T2DM 
Figure 5.1 describes the flow chart of the sample selections, baseline demographic 
and clinical characteristics of Medicare beneficiaries with HIV/AIDS.  It also presents the 
multivariate results of PI use on the odds of developing T2DM.  
5.1.1 Flow chart for sample selection for aim 1 and 2 
Using 2013 to 2017 Medicare data with 1 million Medicare beneficiaries, we 
generated study aims 1 and 2 samples in three main segments as shown in figure 5.1. First, 
we identified 2,627 beneficiaries with diagnosis of HIV/AIDS from the Medicare 
outpatient and inpatient files. Second, we identified 182,007 beneficiaries with diagnosis 
of T2DM from the Medicare outpatient and inpatient file. Exactly 66,388 beneficiaries 
with diagnosis during the washout period (Jan 1 to July 1, 2013) were excluded, resulting 
in a total of 115,619 beneficiaries with T2DM. We excluded a total of 115,100 
beneficiaries who had no record of HIV/AIDS diagnosis, to obtain a sample of 2,627 
HIV/AIDS beneficiaries, which were either diagnosed with T2DM (case) or not (control). 
Third, a total of 183 beneficiaries were excluded if (1), they were enrolled in an HMO 
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plan or (2), if they were not continuously enrolled in Part A and B plan resulting in 2,444 
beneficiaries with HIV/AIDS. After excluding 91 beneficiaries diagnosed of T2DM 
before treatment with PIs, a total of 2,353 HIV/AIDS positive beneficiaries were selected 
in the final sample. The final sample consists of 342 HIV/AIDS positive beneficiaries 
with diagnosis of T2DM (case) and 2,011 HIV/AIDS positive beneficiaries without a 













































Figure 5.1 Sample selection flow chart for study aims 1 & 2 
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5.1.2  Baseline characteristics of matched and unmatched samples  
5.1.2.1 PI versus non-PIs  
 Table 5.1 below shows a comparison of baseline demographic and clinical 
characteristics of beneficiaries between PI and non-PI therapy groups for both matched and 
unmatched selected beneficiaries. In the complete sample, beneficiaries treated with PIs 
significantly differ from beneficiaries treated with non-PIs in terms of age groups (65+ years: 
21.2 % vs. 28.5 %; p=0.001), race category (Caucasians: 42.1 % vs. 49.5 %; p=0.007), CCI ( 
3+: 34.1 % vs. 28.9 %; p=0.036) and dual eligibility status (p=0.0548). However, both groups 
are similar in terms of gender (female: 24.8 % vs. 27.0 %; p=0.284), census region (Midwest: 
15.9 % vs. 18.7 %; p=0.100) and HBV/HCV status (Positive: 27 % vs. 25.9%; p=0.598).  
A total of 484 beneficiaries per group where matched after 1:1 greedy PS matching, 
based on age, gender, race, region, HBV/HCV, and dual eligibility characteristics. Beneficiary 
characteristics included in the PS matching were balanced between both PI and non-PI 
therapy groups- age group (65+ years: 28.3 % vs. 28.3%, p=1.000), gender (female: 22.9 % 
vs. 22.9 %,p=1.000), race category (Caucasians: 49.0 % vs. 49.0 %; p=1.000), census region 
(Midwest: 16.1% vs. 16.1 %; p=1.000), HBV/HCV (positive: 7.4 % vs. 7.4 %; p=1.000) and 
dual eligibility (yes: 62.6 % vs. 62.6 %; p=1.000). CCI factors were not included in the 
matching. Beneficiaries treated with PIs significantly vary from those treated with non-PIs in 










Table 5.1. Baseline characteristics of beneficiaries treated with PIs vs. non-PIs: Complete and matched sample 
   
PI versus non-PI comparison   
Complete Dataset  Matched Dataset 
    PIs           (n=1005)           
 Non-PI              
(n=766 )     
  
 
PIs            
(n=484)           
 Non-PIs              
(n=484 )       
    N % N % P-Values  N % N % P-Values 
Age Group     
 
     
 
 18 - 44 (Ref.) 152 15.1 103 13.5 
0.001 
 87 18.4 87 18.4 
1.000  
45 - 54 331 32.9 204 26.6  109 22.5 109 22.5 
 55 - 64 309 30.8 241 31.5  150 30.9 150 30.9 
  65+ 213 21.2 218 28.5  138 28.3 138 28.3 





1.000  Male 756 75.2 559 73.0  373 77.1 373 77.1 
 Female 249 24.8 207 27.0  111 22.9 111 22.9 






 Caucasian 423 42.1 379 49.5 
0.007 
 237 49.0 237 49.0 
1.000  African America 494 49.2 334 43.6  218 45.0 218 45.0 
  Other Race 88 8.8 53 6.9  29 6.0 29 6.0 






 Midwest 160 15.9 143 18.7 
0.100 
 78 16.1 78 16.1 
1.000  
Northeast 217 21.6 189 24.7  93 19.2 93 19.2 
 South 467 46.5 326 42.6  225 46.5 225 46.5 
  West 161 16.0 108 14.1  88 18.2 88 18.2 
Hepatitis B & C Virus     
0.598 
 
    
1.000  Negative 734 73.0 568 74.2  448 92.6 448 92.6 














 ≤1 (Ref.) 358 35.6 311 40.6 
0.036 
 186 38.4 251 51.9 
<.0001  2 304 30.3 234 30.6  142 29.3 125 25.8 
  3+ 343 34.1 221 28.9  156 32.2 108 22.3 
Dual Eligibility Status     
 
      
 No 197 19.6 179 23.4 0.0548  181 37.4 181 37.4 1.000 
  Yes 808 80.4 587 76.6    303 62.6 303 62.6   




5.1.2.2  PI versus no-ART  
Table 5.2 compares beneficiary’s baseline demographics and clinical characteristics between 
the group treated with PIs and those not treated with ART for both matched and unmatched 
selected beneficiaries. For the unmatched sample, some of the clinical and demographic 
characteristics of beneficiaries in the PI therapy group are different from beneficiaries in the 
no-ART therapy group -age groups (65+ years: 21.2 % vs. 38.1 %; p=<0.0001), gender 
(female: 24.8 % vs. 29.7 %; p=0.032), race category (Caucasians: 42.1 % vs. 54.5 %; 
p=<.0001), CCI ( 3+: 34.1 % vs. 23.2 %; p=<.0001) and dual eligibility status (Yes: 80.4 % 
vs. 52.2 %; p=<.0001). However, both groups are similar in terms of beneficiaries’ census 
region (Midwest: 15.9 % vs. 15.8 %; p=0.629) and HBV & HCV status (Positive: 22.7 % vs. 
22.7%; p=0.998).  A total of 496 beneficiaries per group where matched after 1:1 greedy PS 
matching, based on age, gender, race, region, HBV/HCV, and dual eligibility characteristics. 
For the PS matched sample, beneficiary characteristics included in the PS matching were 
balanced between both PI and no-ART therapy group pairs - age group (65+ years: 27.8 % vs. 
27.8 %, p=1.000), gender (female: 24.1 % vs. 24.1 %,p=1.000), race category (Caucasians: 
42.7 % vs. 42.7 %; p=1.000), census region (Midwest: 16.9% vs. 16.9 %; p=1.000), HBV & 
HCV (positive: 6.7 % vs. 6.7 %; p=1.000) and dual eligibility (yes: 64.9 % vs. 64.9 %; 
p=1.000).  Beneficiaries in the PI therapy group significantly vary from those in no-ART 










Table 5.2 Baseline characteristics of beneficiaries treated with PIs vs. No-ART therapy groups: Complete and matched sample  
  PI versus No-ART Naive comparison 
  Complete Dataset  Matched Dataset 
    
PIs            
(n=1005)           
 No-ART            
(n=582 )        
PIs           
(n=490)           
 No-ART              
(n=490 )     
  
    N % N % P-Values  N % N % P-Values 
Age Group     
 
     
 
 18 - 44 (Ref.) 152 15.1 89 15.3 
<.0001 
 87 17.8 87 17.8 
1.000  
45 - 54 331 32.9 109 18.7  114 23.3 114 23.3 
 55 - 64 309 30.8 162 27.8  153 31.2 153 31.2 
  65+ 213 21.2 222 38.1  136 27.8 136 27.8 
Gender     
0.032 
     
1.000  Male 756 75.2 409 70.3  372 75.9 372 75.9 
 Female 249 24.8 173 29.7  118 24.1 118 24.1 
Race     
 
     
 
 Caucasian 423 42.1 317 54.5 
<.0001 
 209 42.7 209 42.7 
1.000  African America 494 49.2 226 38.8  245 50.0 245 50.0 
  Other Race 88 8.8 39 6.7  36 7.4 36 7.4 
Census Region     
 
     
 
 Midwest 160 15.9 91 15.9 
0.629 
 83 16.9 83 16.9 
1.000  
Northeast 217 21.6 126 22.0  96 19.6 96 19.6 
 South 467 46.7 251 43.8  217 44.3 217 44.3 
  West 161 16.0 105 18.3  94 19.2 94 19.2 
Hepatitis B & C Virus 
    
0.998      1.000 








  Positive 228 22.7 132 22.7  33 6.7 33 6.7 
Charleson Comorbidity Index     
 
     
 
 ≤1 (Ref.) 358 35.6 295.0 50.7 
<.0001 
 177 36.1 248 50.6 
<.0001  2 304 30.3 152.0 26.1  148 30.2 130 26.5 
  3+ 343 34.1 135.0 23.2  165 33.7 112 22.9 
Dual Eligibility Status           
 
 No 197 19.6 278 47.8 <.0001  172 35.1 172 35.1 1.000 
  Yes 808 80.4 304 52.2    318 64.9 318 64.9   




5.1.3  Distribution of PI class prescription  
Figure 5.1 below shows the distribution of PI prescription by sub-class for the full 
sample. Among selected beneficiaries who were treated with PIs, ritonavir was the most 
frequently prescribed PI (n=388) followed by darunavir (n=236), atazanavir (n=170) and 
lopinavir/ritonavir combination (n=151). Fosamprenavir calcium and nelfinavir mesylate 
have similar PI prescription distributions- (n=30) and (n=21) respectively. Indinavir 
sulfate, tipranavir and saquinavir mesylate were the least prescribed PI sub-class with 
frequencies-n=2, 3 and 4 respectively. 
Figure 5.2 below shows the distribution of PI prescriptions by sub-class in the 
matched sample. After matching, the distribution of PI prescriptions was consistent with 
the distribution in the full sample. Ritonavir was the most frequently prescribed PI 
(n=184) followed by darunavir (n=112), atazanavir (n=81) and lopinavir/ritonavir 
combination (n=73). While fosamprenavir calcium and nelfinavir have similar 
prescription distribution -n=18 and12 respectively, tipranavir, indinavir sulfate and 
saquinavir mesylate were the least prescribed PI sub-class with frequencies-n=1, 2 and 3, 
respectively.  
Figure 5.2 below shows the distribution of PI prescription by sub-class for the full 
sample. Among selected beneficiaries who were treated with PIs, ritonavir was the most 
frequently prescribed PI (n=388) followed by darunavir (n=236), atazanavir (n=170) and 
lopinavir/ritonavir combination (n=151). Fosamprenavir calcium and nelfinavir mesylate 
have similar PI prescription distributions- (n=30) and (n=21) respectively. Indinavir 
sulfate, tipranavir and saquinavir mesylate were the least prescribed PI sub-class with 
frequencies-n=2, 3 and 4 respectively. Figure 5.3 below shows the distribution of PI 
prescriptions by sub-class in the matched sample. After matching, the distribution of PI 




Ritonavir was the most frequently prescribed PI (n=184) followed by darunavir (n=112), 
atazanavir (n=81) and lopinavir/ritonavir combination (n=73). While fosamprenavir 
calcium and nelfinavir have similar prescription distribution -n=18 and12 respectively, 
tipranavir, indinavir sulfate and saquinavir mesylate were the least prescribed PI sub-class 














































































































5.1.4  Unadjusted logistic regression analysis  
 Table 5.3 presents the results of unadjusted logistic regression comparing the odds of 
developing T2DM between PI versus non-PI therapy groups and PIs versus no-ART therapy 
group. Bivariate analysis shows that the odds of developing T2DM was 2.06 times higher in 
beneficiaries treated with PIs than beneficiaries treated with non-PIs (OR:2.06; 95% CI: 1.39-
3.06). In the PI versus no-ART therapy pair, unadjusted results show that the odds of 
developing T2DM was 2.13 times higher in beneficiaries treated with PIs compared to those 

















Table 5.3 Unadjusted association between PI and development of T2DM 




 Non-PIs (Ref) 
 
   




 ART Naive (Ref) 
  
  
  PIs 2.13 1.45 3.14 0.0001 
PI: Protease Inhibitors, OR: Odds ratio, T2DM: Types II diabetes Mellitus, 
ART: Anti-Retroviral Therapy, CI: Confidence Interval 
 
 
5.1.5  Adjusted logistic regression analysis 
5.1.5.1  PIs versus non-PIs  
In the adjusted logistic regression analysis, we controlled for potential 
confounding factors at the baseline. (Table 5.4) We found that the odds of 
developing T2DM between beneficiaries treated with PIs and those treated with 
non-PIs was still significant after adjusting for potential confounders. 
Compared to beneficiaries treated with non-PIs, those treated with PIs were 76 
% more likely to develop T2DM after adjusting for covariates (OR=1.76; 95% 
CI: 1.17-2.64). Only, CCI of 3+ were statistically significantly associated with 
the development of T2DM. Compared to beneficiaries with comorbidity of ≤ 1, 
those with a comorbidity of 3 or more were 2.93 times more likely to develop 











































PIs:Protease Inhibitors, AOR: Adjusted Odds ratio, T2DM:  
Types II diabetes Mellitus, CI: Confidence Interval 
 
5.1.5.2  PIs versus no-ARTs  
In the adjusted logistic regression analysis, we controlled for potential confounding 
factors at the baseline. (Table 5.5) We found that treatment with PIs was still significantly 
associated with higher odds of developing T2DM compared to beneficiaries not treated with 
ARTs, after adjusting for covariate. Compared to beneficiaries in the no-ARTs therapy group, 
Table 5.4 Adjusted logistic regression analysis of factors associated 
with development of T2DM: PIs versus non-PIs therapy group  
    AOR 95 % CI P-Value 
Medication Exposure     
 Non-PIs (Ref) 
  
  
  PIs 1.76 1.17 2.64 0.0066 
Age Group     
 18 - 44 (Ref.)  
 45 - 54 1.20 0.64 2.27 0.6889 
 55 - 64 1.00 0.54 1.85 0.4946 
  65+ 1.31 0.70 2.46 0.3646 
Gender     
 Female (Ref) 
  
 
 Male 0.98 0.63 1.54 0.9313 
Race     
 Caucasian (Ref)    
 African America 1.35 0.87 2.09 0.9811 
  Other Race 1.84 0.88 3.82 0.1966 
Census Region     
 Midwest (Ref) 
  
 
 Northeast 1.04 0.54 2.00 0.6676 
 South 0.88 0.46 1.67 0.6700 
  West 0.90 0.51 1.60 0.7382 
Hepatitis B & C Virus 
   
 
 Negative (Ref) 
   
 
  Positive 1.57 0.82 3.00 0.1741 
Charleson Comorbidity Index     
 ≤1 (Ref) 
  
 2 1.81 1.08 3.05 0.7948 
  3+ 2.93 1.79 4.82 0.0002 
Dual Eligibility Status     
 No (Ref)   






those treated with PIs were 87 % more likely to develop T2DM after adjusting for covariates 
(OR=1.87; 95% CI: 1.25-2.81). Covariates statistically significantly associated were CCI of 
3+ and dual eligibility status. Compared to beneficiaries with comorbidity of ≤ 1, those with 
comorbidity of 3 or more were 3.58 times more likely to develop T2DM after adjusting for 
covariates (OR=3.58; 95% CI: 2.22-5.76). After adjusting for covariates, beneficiaries who 
are eligible to Medicare and Medicaid were 1.55 times more likely to develop T2DM compare 


























Table 5.5 Adjusted logistic regression analysis of factors associated with development of 
T2DM: PIs versus no-ARTs  
    AOR 95 % CI P-Value 
Medication Exposure     
 No-ART (Ref) 
  
  
  PIs 1.87 1.25 2.81 0.0025 
Age Group     
 18 - 44 (Ref.)  
 45 - 54 1.00 0.54 1.85 0.6697 
 55 - 64 0.79 0.42 1.49 0.3241 
  65+ 0.95 0.50 1.84 0.8894 
Gender     
 Female (Ref) 
  
 
 Male 0.91 0.59 1.41 0.6766 
Race     
 Caucasian (Ref)    
 African America 1.64 1.08 2.50 0.5663 
  Other Race 2.02 0.92 4.46 0.2363 
Census Region     
 Midwest (Ref) 
  
 
 Northeast 1.23 0.60 2.49 0.7696 
 South 1.14 0.57 2.25 0.9351 
  West 1.27 0.70 2.31 0.5259 
Hepatitis B & C Virus 
   
 
 Negative (Ref) 
   
 
  Positive 0.91 0.47 1.77 0.7786 
Charleson Comorbidity Index     
 ≤1 (Ref.) 
  
 2 1.60 0.95 2.71 0.4623 
  3+ 3.58 2.22 5.76 <.0001 
Dual Eligibility Status     
 No (Ref)   
  Yes 1.55 0.99 2.43 0.0565 
PI: Protease Inhibitors, AOR: Adjusted Odds ratio, T2DM: Types II diabetes Mellitus,  











5. 2  Racial Disparity In Development of T2DM Following Treatment With PI
 Table 5.6 presents the description of matched samples of African American and 
Caucasian Medicare beneficiaries with HIV/AIDS across each comparison group, the 
unadjusted race-subgroup logistic regression of treatment with PIs and development of 
T2DM, and the multivariate race-subgroup logistic regression of treatment with PIs and 
development of T2DM for each comparison group. 
5.2.1  Descriptive Analysis 
 Tables 5.6 ad 5.7 shows chi-square test results comparing baseline characteristics 
of matched sample of African Americans and Caucasians for balance across PIs versus 
non-PIs and PIs versus no-ARTs therapy groups.  
5.2.1.1 PIs versus non-PIs  
Matched sample of African American sub-groups consists of a total of 218 
beneficiaries per group which are similar in terms of their clinical and demographic 
characteristics - age group (65+ years: 31.7 % vs. 31.7 %, p=1.000), gender (female: 33 % vs. 
33 %,p=1.000), census region (Midwest: 14.7% vs. 14.7 %; p=1.000), HBV & HCV 
(positive: 23.4 % vs. 23.4 %; p=1.000) and dual eligibility (Yes: 68.8 % vs. 68.8 %; p=1.000). 
(Table 5.6) CCI characteristics were not included in the propensity matching process thus, 
beneficiaries in the PIs therapy group were significantly different from beneficiaries in the 
non-PIs therapy group in terms of CCI characteristics. CCI (3+: 41.3 % vs. 26.2 %; p= 0.001).  
Within the Caucasian sub-group, a total of 237 Caucasian beneficiaries per therapy 
group were matched. (Table 5.6) Matched groups are similar in terms of their clinical and 
demographic characteristics - age group (65+ years: 35.5 vs. 35.5 %, p=1.000), gender 






HBV & HCV (positive: 7.2 % vs. 7.2 %; p=1.000) and dual eligibility (yes: 56.1 % vs. 56.1 
%; p=1.000). Beneficiaries in the PIs therapy group were significantly different from 
beneficiaries in the non-PIs therapy group in terms of CCI characteristics. CCI (3+: 30.4 % 










Table 5.6 Baseline characteristics of matched sample of African American and Caucasian: PIs versus non-PIs  
    African Americans    Caucasians   
    
PIs            
(n=218)           
 Non-PIs       
(n=218 )     
  
 
PIs            
(n=237)           
 Non-PIs              
(n=237 )       
Covariates N % N % P  N % N % P 
Age Group     
 
     
 
 18 - 44 (Ref.) 43 19.7 43 19.7 
1.000 
 32 13.5 32 13.5 
1.00  
45 - 54 38 17.4 38 17.4  53 22.4 53 22.4 
 55 - 64 68 31.2 68 31.2  69 29.1 69 29.1 
  65+ 69 31.7 69 31.7  83 35.0 83 35.0 





1.000  Male 146 67.0 146 67.0  203 85.7 203 85.7 
 Female 72 33.0 72 33.0  34 14.4 34 14.4 






 Midwest 32 14.7 32 14.7 
1.000 
 44 18.6 44 18.6 
1.000  
Northeast 43 19.7 43 19.7  41 17.3 41 17.3 
 South 125 57.3 125 57.3  92 38.8 92 38.8 
  West 18 8.3 18 8.3  60 25.3 60 25.3 
Hepatitis B & C Virus     
1.000 
 
    
1.000  Negative 167 76.6 167 76.6  220 92.8 220 92.8 
  Positive 51 23.4 51 23.4  17 7.2 17 7.2 






 ≤1 (Ref.) 76 34.9 110 50.5 
0.001 
 92 38.8 124 52.3 
0.005  2 52 23.9 51 23.4  73 30.8 67 28.3 
  3+ 90 41.3 57 26.2  72 30.4 46 19.4 
Dual Eligibility Status     
 
      
 No 68 31.2 68 31.2 1.000  104 43.9 104 43.9 1.000 
  Yes 150 68.8 150 68.8    133 56.1 133 56.1   






5.2.1.2 PIs versus no-ARTs 
Matched sample of African American sub-groups consists of a total of 245 
beneficiaries per group.(Table 5.7) Beneficiaries in the PIs therapy group were similar in 
terms of their clinical and demographic characteristics - age group (65+ years: 22.5 % vs. 22.5 
%, p=1.000), gender (female: 30.2 % vs. 30.2 %,p=1.000), census region (Midwest: 16.0% vs. 
16.0 %; p=1.000), HBV & HCV (positive: 7.8 % vs. 7.8 %; p=1.000) and dual eligibility 
(Yes: 73.1 % vs. 73.1 %; p=1.000) compared to beneficiaries in the no-ARTs therapy group. 
CCI characteristics were not included in the propensity matching process thus, beneficiaries in 
the PIs group were significantly different from beneficiaries in the non-PIs group in terms of 
CCI characteristics. CCI (3+: 37.1 % vs. 25.8 %; p= 0.003).  
Within the Caucasian sub-group, a total of 209 Caucasian beneficiaries per therapy 
group were matched. (Table 5.7) Matched groups are similar in terms of their clinical and 
demographic characteristics - age group (65+ years: 34.5 % vs. 34.5 %, p=1.000), gender 
(female: 13.4 % vs. 13.4 %, p=1.000), census region (Midwest: 19.1 % vs. 19.1 %; p=1.000), 
HBV & HCV (positive: 5.7 % vs. 5.7 %; p=1.000) and dual eligibility (yes: 53.1 % vs. 
53.1%; p=1.000). Beneficiaries in the PIs therapy group were significantly different from 
beneficiaries in the no-ARTs therapy group based on CCI characteristics. CCI (3+: 31.1 % vs. 















PI: Protease Inhibitors, ART: Anti-Retroviral Therapy
 
 
Table 5.7 Baseline characteristics of matched sample of race subgroups: PIs versus no-ARTs  
    African American    Caucasians   
    
PIs            
(n=245)           
 Non-PIs             
(n=245 )        
PIs            
(n=209)           
  ART Naive              
(n=209 )       
    N % N % P  N % N % P 
Age Group     
 
     
 
 18 - 44 (Ref.) 60 24.5 60 24.5 
1.000 
 19 9.1 19 9.1 
1.000  
45 - 54 53 21.6 53 21.6  50 23.9 50 23.9 
 55 - 64 77 31.4 77 31.4  68 32.5 68 32.5 
  65+ 55 22.5 55 22.5  72 34.5 72 34.5 





1.000  Male 171 69.8 171 69.8  181 86.6 181 86.6 
 Female 74 30.2 74 30.2  28 13.4 28 13.4 






 Midwest 38 15.5 38 15.5 
1.000 
 40 19.1 40 19.1 
1.000  
Northeast 48 19.6 48 19.6  38 18.2 38 18.2 
 South 142 58.0 142 58.0  68 32.5 68 32.5 
  West 17 6.9 17 6.9  63 30.1 63 30.1 
Hepatitis B & C Virus 
    
1.000 
 
    
1.000  Negative 226 92.2 226 92.2  197 94.3 197 94.3 
  Positive 19 7.8 19 7.8  12 5.7 12 5.7 






 ≤1 (Ref.) 86 35.1 100 50.5 
0.003 
 77 36.8 132 50.4 
0.008  2 68 27.8 47 23.7  67 32.1 74 28.2 
  3+ 91 37.1 51 25.8  65 31.1 56 21.4 
Dual Eligibility Status            
 No 66 26.9 66 26.9 1.000  98 46.9 98 46.9 1.000 






5.2.2  Unadjusted logistic regression analysis  
Table 5.8 shows the results of unadjusted logistic regression of the odds of developing 
T2DM between therapy group pairs for African American and Caucasian race subgroups. In 
the PIs versus non-PIs therapy groups, results show that the odds of developing T2DM is 2.00 
times higher in African American beneficiaries treated with PIs compared to African 
Americans treated with non-PIs (OR:2.00; 95% CI:1.14 – 3.52). Caucasians treated with PIs 
are 98 % more likely to develop T2DM than Caucasians treated with non-PIs (OR:1.98; 95% 
CI:1.07-3.65).  
In the PIs versus no-ARTs therapy groups, the odds of developing T2DM is 2.23 times 
higher among African Americans treated with PIs compared to African Americans who were 
not treated with ART (OR:2.23; 95% CI:1.17 -4.25). The odds of developing T2DM is 2.18 
times higher in Caucasian beneficiaries treated with PIs compared to those not treated with 






PI: Protease Inhibitors, OR: Odds ratio, T2DM: Types II diabetes Mellitus, ART: Anti-
Retroviral Therapy, CI: Confidence Interval 
 
5.2.3  Multivariate sub-group analysis 
Tables 5.9 and 5.10 show the multivariate logistic results of race sub-group 
analysis of PIs use on the development of T2DM for both therapy groups. 
5.2.3.1  PIs versus non-PIs 
In the adjusted logistic regression for race/ethnicity sub-group analysis, we controlled 
for potential confounding factors at the baseline. (Table 5.9) We found that among African 
Americans, the odds of developing T2DM between beneficiaries treated with PIs and those 
treated with non-PIs was still significant after adjusting for potential confounders. Compared 
to African American beneficiaries treated with non-PIs, those treated with PIs were 86 % 
more likely to develop T2DM after adjusting for covariates (OR=1.86; 95% CI: 1.03-3.36). 
Among other factors controlled, only CCI of 3+ were statistically significantly associated 
with the development of T2DM. Compared to African American beneficiaries with 
comorbidity of ≤ 1, those with a comorbidity of 3 or more were 2.67 times more likely to 
develop T2DM after adjusting for covariates (OR=2.67; 95% CI: 1.31-5.42). Compared to 
African American beneficiaries with without dual eligibility, those with dual eligibility were 
2.34 times more likely to develop T2DM after adjusting for covariates (OR=2.34; 95% CI: 
1.10-4.95). 
Table 5.8 Unadjusted association between PI use and development of T2DM: Race Sub-
group  
    African Americans 
 
Caucasians 
    OR 95 % CI 
P-




   
  
   
 
 Non-PI (Ref) 
 
    
 
   
  PIs 2.00 1.14 3.52 0.0158  1.98 1.07 3.65 0.0293 
Medication Exposure 
   
  
   
 
 ART Naive (Ref) 
   
 
   






Among Caucasian beneficiaries, the odds of developing T2DM between beneficiaries 
treated with PIs and those treated with non-PIs was still significant after adjusting for 
potential confounders. Compared to Caucasian beneficiaries treated with non-PIs, those 
treated with PIs were 3.38 times more likely to develop T2DM after adjusting for covariates 
(OR=1.81; 95% CI: 1.02-3.22). Among other factors controlled, only CCI of 3+ were 
statistically significantly associated with the development of T2DM. Compared to African 
American beneficiaries with comorbidity of ≤ 1, those with a comorbidity of 3 or more were 
























5.2.3.2  PIs versus no-ARTs 
We controlled for potential confounding factors at the baseline in the adjusted logistic 
regression for the race/ethnicity sub-group analysis. (Table 5.10). Results show that among 
African Americans, the odds of developing T2DM between beneficiaries treated with PI and 
those not treated with ART was still significant after adjusting for potential confounders.
Table 5.9. Multivariate logistic regression analysis of factors associated with development 
of T2DM: Race sub-group comparison of PI versus non-PI therapy group  
    African Americans 
 
Caucasians 
    AOR 95 % CI P  AOR 95 % CI P 
Medication Exposure      
  
  
 Non-PIs (Ref) 
  
   
  
  
  PIs 1.86 1.03 3.36 0.0390  1.81 1.02 3.22 0.0427 
Age Group          
 18 - 44 (Ref.)    
 45 - 54 2.26 0.93 5.48 0.1568  0.55 0.22 1.38 0.4374 
 55 - 64 1.61 0.69 3.77 0.9577  0.50 0.20 1.23 0.2225 
  65+ 1.76 0.71 4.38 0.6861  0.75 0.31 1.84 0.6330 
Gender      
  
  





 Male 0.90 0.50 1.63 0.7304  1.05 0.52 2.14 0.8864 
Census Region      
  
  





 Northeast 0.98 0.30 3.23 0.8995  1.01 0.44 2.30 0.7150 
 South 0.94 0.29 3.02 0.9740  0.76 0.33 1.75 0.5291 
  West 0.87 0.30 2.49 0.6961  0.89 0.43 1.83 0.9289 
Hepatitis C Virus 
   
  
   
 
 Negative (Ref) 
   
  
   
 
  Positive 2.16 0.91 5.17 0.0827  1.07 0.38 3.04 0.8963 
Charleson Comorbidity Index      
  
  




 2 2.29 1.08 4.83 0.2734  1.40 0.67 2.93 0.3970 
  3+ 2.67 1.31 5.42 0.0489  3.38 1.67 6.84 0.0006 
Dual Eligibility Status          
 No (Ref)      






Compared to African American beneficiaries not treated with ART, those treated with 
PIs were 2.05 times more likely to develop T2DM after adjusting for covariates (OR=2.05; 
95% CI: 1.03-4.09). Among other factors controlled, only CCI of 3+ was statistically 
significantly associated with the development of T2DM. African American beneficiaries with 
a comorbidity of ≤ 1 were 4.66 times more likely to develop T2DM than those with a 
comorbidity of 3 or more after adjusting for covariates. 
Among Caucasian beneficiaries, the odds of developing T2DM between beneficiaries 
treated with PI and those not treated with ART was still significant after adjusting for 
potential confounders. Compared to Caucasian beneficiaries not treated with ART, those 
treated with PIs were 1.96 times more likely to develop T2DM after adjusting for covariates 
(OR=1.96; 95% CI: 1.14-3.39). Among factors that were controlled in the logistic regression, 
only CCI of 3+ were statistically significantly associated with the development of T2DM. 
Caucasian beneficiaries with a comorbidity of ≤ 1  were 2.83 times more likely to develop 
T2DM than those with a comorbidity of 3 or more after adjusting for covariates (OR=2.38; 










Table 5.10 Multivariate logistic regression analysis of factors associated with 
development of T2DM: Race sub-group comparison of PI versus no-ARTs   
    African Americans 
 
Caucasians 




   
  
  
 No-ART (Ref) 
  
   
  
  
  PIs 2.05 1.03 4.09 0.0414  1.96 1.14 3.39 0.0158 
Age Group          
 18 - 44 (Ref.)    
 45 - 54 0.46 0.17 1.25 0.9103  1.50 0.64 3.50 0.5205 
 55 - 64 0.32 0.12 0.90 0.1671  1.23 0.52 2.93 0.8325 
  65+ 0.33 0.11 1.02 0.2765  1.52 0.63 3.69 0.4930 
Gender      
  
  





 Male 0.93 0.41 2.11 0.8656  0.95 0.54 1.66 0.8449 
Census Region      
  
  





 Northeast 1.81 0.69 4.76 0.2796  0.85 0.24 2.94 0.4600 
 South 1.31 0.46 3.71 0.9883  1.27 0.40 3.99 0.5817 
  West 1.27 0.53 3.03 0.8795  1.29 0.45 3.64 0.4310 
Hepatitis B & C 
Virus 
   
  
   
 
 Negative (Ref) 
   
  
   
 




   
  
  




 2 1.71 0.72 4.07 0.5303  1.42 0.69 2.91 0.5896 
  3+ 4.66 2.06 10.54 0.0002  2.83 1.52 5.27 0.0015 
Dual Eligibility 
Status          
 No (Ref)      
  Yes 1.17 0.56 2.47 0.6792  1.61 0.87 2.98 0.1288 
PI: Protease Inhibitors, OR: Odds ratio, T2DM: Types II diabetes Mellitus, ART: Anti-
Retroviral Therapy, CI: Confidence Interval 
 
5. 3 Economic Burden of Comorbid T2DM 
Section 5.3 describes the sample selection flow chart for study aim 3, baseline 
demographic and clinical characteristics of selected beneficiaries and the multivariate 
results of the impact of T2DM on different costs. The costs considered were total inpatient 
cost, total outpatient cost, total prescription cost, total OOP cost, total Medicare cost and 






5.3.1 Flow chat for sample selection 
Using 2013 to 2017 Medicare data with 1 million Medicare beneficiaries, we 
generated the study aim 3 sample in three steps. (Figure 5.4). First, we identified 2,627 
beneficiaries with diagnosis of HIV/AIDS and 182,007 beneficiaries with diagnosis of 
T2DM. Second, we excluded a total of 181,488 beneficiaries, who have no record of 
HIV/AIDS diagnosis. Thus, leaving behind a total of 2,627 HIV/AIDS beneficiaries with 
or without T2DM diagnosis. Third, a total of 118 beneficiaries were exclude (1), if they 
either were enrolled in HMO plan or (2) if they were not continuously enrolled in Part A 
and B plan. A total of 2,509 HIV/AIDS positive beneficiaries were selected in the final 
sample or (3), if beneficiary have ESRD. The final sample consists of 498 HIV/AIDS 
positive beneficiaries with a diagnosis of T2DM (Case) and 2,011 HIV/AIDS positive 




























    
Figure 5.4 Sample selection flow chart for study aims 3  
Diagnosis of HIV/AIDS  
N=2,627 
Diagnosis of T2DM 
N=182,007 
HIV/AIDS beneficiaries 
with or without T2DM  
N=2,627 
• Enrolled in HMO insurance plan 
• Not continuously enrolled in Part A and B 
• Presence of ESRD 
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5.3.2  Descriptive analysis 
Table 5.11 summarizes baseline characteristics of beneficiaries with HIV/AIDS, 
distinguishing between those with comorbid T2DM and those without comorbid T2DM. 
Except for hepatitis B and C variables, low income subsidy and dual eligibility variables, 
all other baseline characteristics were statistically significantly different between 
beneficiaries with a history of T2DM and those without. Beneficiaries in the T2DM 
history group and those in the non-T2DM history group are statistically significantly 
different in terms of age-group (P= 0.036), gender; p=0.015, race category; p=0.000, 
region; p= 0.008 and CCI scores, (P= <.0001). Beneficiaries with a history of T2DM and 
individuals without a history of T2DM are similar in terms of treatment with anti-
retroviral drugs, hepatitis B/C virus, (p=0.770), and Medicare and Medicaid dual 



















Table 5.11. Baseline characteristics of HIV/AIDS positive beneficiaries with 
T2DM versus those without T2DM (N = 2,509)  
    T2DM Status 
    
T2DM                   
(n=498)           
 Non-T2DM         
(n=2011)     
  
    N % N % P-Value 
Treatment with ART 
     
 Non-PIs  694 69.1 402 69.2 0.9549 
  PIs 311 30.95 179 30.8   
Age Group 
     
 18 - 44 (Ref.) 18 3.6 97 4.8 
 
 45 - 54 43 8.6 205 10.2 0.0360 
 55 - 64 116 23.3 556 27.7 
 
  65+ 321 64.5 1153 57.3   
Gender 
     
 Male 340 68.3 1482 73.7 0.0150 
 Female 158 31.7 529 26.3   
Race 
    
 
 Caucasian 188 37.8 970 48.2 
 
 African America 265 53.2 874 167.0 0.0000 
  Other Race 45 9.0 43.46 8.3   
Census Region 
    
 
 Midwest 77 15.5 341 17.0 
 Northeast 117 23.5 447 22.3 0.0080 
 South 248 49.9 881 44.0 
 
  West 55 11.1 333 16.6   
Hepatitis B & C Virus 
     
 Negative 438 88.0 1759 87.5 0.7700 
  Positive 60 12.1 252 12.5   
Charleson Comorbidity Index 
     
 0 88 17.7 387 19.2  
 1 235 47.2 1184 58.9  
 2 112 22.5 299 14.9 <.0001 
  3+ 63 12.7 141 7.0   
Low Income Subsidy 
     
 No 131 28.9 581 28.9 0.2520 
  Yes 367 73.7 1430 71.1   
Dual Eligibility Status 
 
   
 
 No 133 26.7 583 29.0 0.3120 
  Yes 365 73.3 1428 71.0   
            
 
 








Table 5.12 presents the unadjusted averages costs for different healthcare costs 
between HIV/AIDS positive beneficiaries with comorbid T2DM and those without. On 
average, the cost of hospitalization for individuals with comorbid T2DM was statistically 
significantly higher than the cost of hospitalization for individuals without comorbid 
T2DM: (mean diff.: 32, 622; 95 % CI: 26,329-38,915; p= <.0001). The outpatient cost for 
individuals with a T2DM history was statistically significantly higher than in individuals 
without comorbid T2DM (mean diff.: 14, 894; 95 % CI: 11,402-18,385; p= <.0001). 
Compared to individuals with comorbid T2DM, those without comorbid T2DM had 
statistically significantly higher Medicare costs. (mean diff.: 56,459; 95 % CI: 45,261-
67,658; p-value= <.0001). Beneficiaries with comorbid T2DM incur statistically 
significantly higher OOP costs than those without comorbid T2DM (mean diff.: 5,109; 95 
% CI: 4,237-5,981; p-value= <.0001). Prescription costs were statistically significantly 
higher for individuals with comorbid T2DM than those without (mean diff.: 17,974; 95 % 
CI: 9,301-26,648; p= <.0001]. Individuals with comorbid T2DM incurred higher overall 
total medical costs than individuals without comorbid T2DM (mean diff.: 65491; 95 % 
















Table 5.12. Average healthcare costs of HIV/AIDS positive beneficiaries with T2DM versus those without T2DM  
    T2DM (n=496) No T2DM (n=2011)   
    Mean ± Std Mean ± Std 
Mean Cost 
Difference 95 % CI P- Value 
Total hospitalization cost            
    57,628 ± 101,295 25,006 ± 53,882 32,622 26,329 38,915 <.0001 
Total outpatient cost      
<.0001   26,600 ± 46,885 11,706 ± 36,436 14,894 11,402 18,385 
Total prescription drug 
cost            
  105,315 ± 114,061 87,341 ± 91,886 17,974 9,301 26,648 <.0001 
Total Medicare cost           
<.0001   159,901 ± 158,736 103,442 ± 111,759 56,459 45,261 67,658 
Total OOP cost           
<.0001     9,976 ±13,514 4,868 ±789 5,109 4,237 5,981 
Total medical cost            
<.0001     189,543 ± 176,920 124,052 ± 125,048 65,491 5,2,984 77,988 





5.3.5 Unadjusted GLM analysis of the impact of comorbid T2DM on healthcare costs 
Table 5.13 shows the results of unadjusted GLM analysis with log link and gamma 
distribution, comparing different healthcare costs between individuals with comorbid T2DM 
and those without. We found that comorbid T2DM in HIV/AIDS is statistically significantly 
associated with a 73.19% [(e0.54921-1) *100] increase in hospitalization costs (p=<.0001) 
compared to individuals without T2DM on average. Compared to HIV/AIDS positive 
beneficiaries without T2DM, those with T2DM had 102.3 % [(e0.7946-1) *100] 
higher total outpatient costs on average. (P=<.0001) Compared to HIV/AIDS positive 
beneficiaries without T2DM, those with T2DM had 16.57 % [(e0.1533-1) *100] higher 
prescription drug costs on average. (p=0.0023). We also found that compared to HIV/AIDS 
positive beneficiaries without T2DM, those with T2DM had 103.24% [(e0.7092-1) *100] higher 
total OOP costs on average. Considering total Medicare and total medical costs, compared to 
HIV/AIDS positive beneficiaries without T2DM, those with T2DM had 54.22% [(e0.4332-1) 
















Table 5.13 Unadjusted GLM analysis of the effect of comorbid T2DM on total 
healthcare costs   
    Estimates  95 % CI P-Value 
Total Hospitalization Costs     
T2DM     
 Negative (Ref)     
  Positive 0.5492 0.4355 0.6630 <.0001 
Total Outpatient Cost     
T2DM     
 Negative (Ref)     
  Positive 0.7946 0.6797 0.9094 <.0001 
Total Prescription Drug Cost     
T2DM     
 Negative (Ref)     
  Positive 0.1533 0.0547 0.2519 0.0023 
Total OOP Cost     
T2DM     
 Negative (Ref)     
  Positive 0.7092 0.6049 0.8135 <.0001 
Total Medicare Cost     
T2DM     
 Negative (Ref)     
  Positive 0.4332 0.3405 0.5259 <.0001 
Total Medical Cost     
T2DM     
 Negative (Ref)     
  Positive 0.4222 0.3330 0.5113 <.0001 
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence 
Interval 
 
5.3.6 Adjusted GLM analysis of effect of comorbid T2DM on different costs  
 Table 5.14 to tables 5:18 summarizes the multivariate GLM analysis of the impact of 
T2DM on different costs. GLM analysis controls for the baseline characteristics of the 
beneficiary such as: age-group, gender, region of the US, race category, CCI, Hepatitis B/C 






5.3.5.1 Total hospitalization costs 
 After controlling for potential confounders at the baseline in the GLM analysis (Table 
5.14) the impact of T2DM on hospitalization was still statistically significantly higher in 
beneficiaries with T2DM compared to those without T2DM. We found that on average, 
HIV/AIDS positive beneficiaries with comorbid T2DM had a 63.34 % [(e0.4907-1) *100] 
increase in total hospitalization cost (p=<.0001) compared to HIV/AIDS beneficiaries without 
comorbid T2DM. 
Other covariates that are statistically significantly associated with changes in total 
hospitalization costs include race category, southern region, hepatitis B/C Virus, and CCI-1 
categories. Compared to Caucasian beneficiaries with HIV/AIDS, African American 
HIV/AIDS positive beneficiaries had 39.98 % higher total hospitalization costs on average 
(p=<.0001) while HIV/AIDS beneficiaries of ‘other race’ groups had 48.38 % higher total 
hospitalization costs on average (p=0.0023). Compared to HIV/AIDS positive beneficiaries 
living in the Midwest region, those living in the Southern region had 16.48 % lower total 
hospitalization costs on average (p=0.0501). Compared to HIV/AIDS beneficiaries without 
hepatitis B/C virus comorbidity, those with hepatitis B/C virus comorbidity had 40.78 % 
higher total hospitalization costs on average (p=<.0001). Compared to HIV/AIDS 
beneficiaries without any comorbidity (CCI=0), those with a comorbidity of 1 (CCI=1) had 
52.14 % lower total hospitalization costs on average (p=0.0054).  
Antiretroviral treatment with PIs did not significantly impact hospitalization cost 
compare to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated 
with non-PIs, those treated with PI had a 9.01 % lower total hospitalization cost on average, 




There was no statistically significant differences found in total hospitalization costs 
between: male and female beneficiaries (p=0.5792), those living in the Midwest and those 
living in the Northeast region ((p=0.8754), and those living in Midwest and those living in the 
Western region (p=0.1852), between beneficiaries with CCI=0 and those with CCI=2 
(p=0.0857), between beneficiaries with CCI=0 and those with CCI=3 (p=0.9529), and 



















Table 5.14 Adjusted GLM analysis of the effect of comorbid T2DM on total 
hospitalization costs  
    Estimates  95 % CI P-Value 
Intercept 10.8392 10.2662 11.4121 <.0001 
T2DM     
 Negative (Ref)     
  Positive 0.4907 0.3558 0.6256 <.0001 
Treatment with ART     
 Non-PIs (Ref)     
  PIs -0.0863 -0.2186 0.0459 0.2007 
Age Group     
 18 - 44 (Ref.)     
 45 - 54 0.0473 -0.1651 0.2596 0.6626 
 55 - 64 0.0413 -0.1661 0.2486 0.6963 
  65+ 0.1011 -0.1109 0.3132 0.3499 
Gender     
 Female (Ref)     
 Male -0.0408 -0.1851 0.1035 0.5792 
Race     
 Caucasian (Ref)     
 African America 0.3363 0.1970 0.4756 <.0001 
  Other Race 0.3946 0.1409 0.6483 0.0023 
Census Region     
 Midwest (Ref)     
 Northeast -0.0162 -0.2187 0.1863 0.8754 
 South -0.1801 -0.3603 0.0001 0.0501 
  West 0.1549 -0.0743 0.3842 0.1852 
Hepatitis C Virus     
 Negative (Ref)     
  Positive 0.3420 0.1953 0.4888 <.0001 
Charleson Comorbidity Index     
 0 (Ref)     
 1 -0.7368 -1.2556 -0.2180 0.0054 
 2 -0.4515 -0.9665 0.0634 0.0857 
  3+ 0.0154 -0.4959 0.5267 0.9529 
Dual Eligibility Status     
 No     
  Yes 0.0474 -0.1001 0.1948 0.5290 
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: 




5.3.5.2 Total outpatient costs 
 After controlling for potential confounders at the baseline in the GLM analysis (Table 
5.15) the impact of T2DM on total outpatient cost was still statistically significantly higher 
among beneficiaries with comorbid T2DM than to those without comorbid T2DM. Results 
further show that, on average, HIV/AIDS positive beneficiaries with comorbid T2DM had a 
50.26% [(e0.4072-1) *100] increase in total outpatient cost (p=<.0001) compared to HIV/AIDS 
beneficiaries without comorbid T2DM . 
Other covariates that are statistically significantly associated with changes in total 
outpatient cost include age group (45-54), race, region and CCI. Compared to HIV/AIDS 
positive beneficiaries living in the Midwestern region, those living in the Northeast region had 
a 27.10 % lower total outpatient cost on average (p=0.0195). The Southern region had 25.01 
% lower total outpatient costs on average (p=0.0187), and the Western region had 26.35 % 
lower total outpatient costs on average (p=0.0359). Compared to HIV/AIDS beneficiaries 
without any comorbidity (CCI=0), those with a comorbidity of: CCI=1 had 59.94 % higher 
total outpatient costs on average (p=0.0045), CCI=2 had 243.36 % higher total outpatient 
costs on average (p=<.0001), and CCI=3+ had 577.34 % higher total outpatient cost on 
average (p=<.0001). 
Antiretroviral treatment with PIs did not significantly impact outpatient cost compare 
to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated with non-
PIs, those treated with PI had a 4.24 % higher total outpatient cost on average, however, 
incremental cost was not statistically significant (p=0.5265). There was no statistically 
significant difference in changes in total outpatient cost between: age groups, male and female 
beneficiaries (p=0.0662), and beneficiaries with dual eligibility and those without dual 

















































GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence  
Interval, PI: Protease Inhibitor, ART: Antiretroviral Therapy 
 
 
Table 5.15 Adjusted GLM analysis of the effect of comorbid T2DM on total 
outpatient costs  
    Estimates  95 % CI P-Value 
Intercept 8.3138 7.9020 8.7256 <.0001 
T2DM     
 Negative (Ref)     
  Positive 0.4072 0.2677 0.5467 <.0001 
Treatment with ART     
 Non-PIs (Ref)     
  PIs 0.0415 -0.0869 0.1698 0.5265 
Age Group     
 18 - 44 (Ref.)     
 45 - 54 0.2322 0.0242 0.4403 0.0287 
 55 - 64 0.1896 -0.0084 0.3877 0.0605 
  65+ 0.1380 -0.0690 0.3450 0.1913 
Gender     
 Female (Ref)     
 Male -0.0810 -0.2228 0.0607 0.2625 
Race     
 Caucasian (Ref)     
 African America 0.1074 -0.0352 0.2499 0.1399 
  Other Race -0.1883 -0.4228 0.0462 0.1155 
Census Region     
 Midwest (Ref)     
 Northeast -0.2398 -0.4411 -0.0385 0.0195 
 South -0.2232 -0.4092 -0.0372 0.0187 
  West -0.2339 -0.4524 -0.0154 0.0359 
Hepatitis C Virus     
 Negative (Ref)     
  Positive 0.0708 -0.0821 0.2237 0.3641 
Charleson Comorbidity Index     
 0 (Ref)     
 1 0.4696 0.1453 0.7939 0.0045 
 2 1.2336 0.9051 1.5621 <.0001 
  3+ 1.9130 1.5811 2.2450 <.0001 
Dual Eligibility Status     
 No     




5.3.5.3 Total OOP  
 After controlling for potential confounders at the baseline in the GLM analysis (Table 
5.16) the impact of T2DM on total OOP cost was still statistically significantly higher among 
beneficiaries with comorbid T2DM compared to those without comorbid T2DM. Results 
show that on average, HIV/AIDS positive beneficiaries with comorbid T2DM  had a 59.15% 
[(e0.4647-1) *100] increase in total OOP cost (p=<.0001) compared to HIV/AIDS beneficiaries 
without comorbid T2DM. 
Other covariates statistically significantly associated with changes in total OOP cost 
include race, hepatitis B/C Virus and CCI characteristics. Compared to Caucasian 
beneficiaries with HIV/AIDS, beneficiaries of ‘other race’ group had 44.40 % lower total 
OOP costs on average (p=0.0009). Compared to HIV/AIDS beneficiaries without hepatitis 
B/C virus comorbidity, those with hepatitis B/C virus comorbidity had 32.14 % higher total 
OOP costs on average (p=<0.0001). Compared to HIV/AIDS beneficiaries without any 
comorbidity (CCI=0), those with a comorbidity of: CCI=1 had 36.15  % higher total OOP 
costs on average (p=0.0466), CCI=2 had 119.88 % higher outpatient costs on average 
(p=<.0001), and CCI=3+ had 274.75 % higher OOP costs on average (p=<.0001).  
Antiretroviral treatment with PIs did not significantly impact OOP cost compare to 
treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated with non-PIs, 
those treated with PI had a 6.97 % higher total OOP cost on average, however, incremental 
cost was not statistically significant (p=0.2590). We also found that there was no statistically 
significant difference in changes to total OOP costs between: age groups, region, male and 






Table 5.16 Adjusted GLM analysis of the effect of comorbid T2DM on total OOP 
costs  
    Estimates  95 % CI P-Value 
Intercept 7.9091 7.5290 8.2892 <.0001 
T2DM     
 Negative (Ref)     
  Positive 0.4647 0.3366 0.5929 <.0001 
Treatment with ART     
 Non-PIs (Ref)     
  PIs 0.0674 -0.0496 0.1844 0.2590 
Age Group     
 18 - 44 (Ref.)     
 45 - 54 0.1357 -0.3261 0.2548 0.1628 
 55 - 64 0.1479 -0.3318 0.3359 0.1147 
  65+ 0.1788 -0.2713 0.3734 0.4221 
Gender     
 Female (Ref)     
 Male -0.0113 -0.1403 0.1177 0.8635 
Race     
 Caucasian (Ref)     
 African America -0.0182 -0.1444 0.1080 0.7774 
  Other Race -0.3674 -0.5836 -0.1512 0.0009 
Census Region     
 Midwest (Ref)     
 Northeast -0.1409 -0.3230 0.0411 0.1292 
 South -0.0921 -0.2554 0.0712 0.2691 
  West -0.1182 -0.3187 0.0823 0.2478 
Hepatitis C Virus     
 Negative (Ref)     
  Positive 0.2787 0.1387 0.4186 <.0001 
Charleson Comorbidity Index     
 0 (Ref)     
 1 0.3086 0.0046 0.6125 0.0466 
 2 0.7879 0.4810 1.0949 <.0001 
  3+ 1.3211 1.0121 1.6301 <.0001 
Dual Eligibility Status     
 No     
  Yes -0.0578 -0.1909 0.0753 0.3945 
        GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence 







5.3.5.4 Total prescription cost 
 After controlling for potential confounders at the baseline in the GLM analysis (Table 
5.17) the difference in total prescription costs between individuals with comorbid T2DM and 
those without comorbid T2DM was no longer statistically significant. We found that 
compared to HIV/AIDS beneficiaries without comorbid T2DM, those with T2DM had 6.97 % 
[(e0.0674-1) *100] higher total prescription costs on average, however, the incremental cost was 
not statistically significant. (p=0.3113). 
Other covariates statistically significantly associated with changes in total prescription 
drug cost include hepatitis B/C and CCI. Compared to HIV/AIDS positive beneficiaries 
without hepatitis B/C, those diagnosed with hepatitis B/C had 21.12 % higher total 
prescription costs on average (p=0.0076). Compared to HIV/AIDS beneficiaries without any 
comorbidity (CCI=0), those with a comorbidity of: CCI=1 had 140.37 % higher total 
prescription costs on average (p=<.0001), CCI=2 had 223.88 % higher total prescription costs 
on average (p=<.0001), CCI=3+ had 255.41 % higher total prescription costs on average 
(p=<.0001).  
Antiretroviral treatment with PIs did not significantly impact prescription drug cost 
compare to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated 
with non-PIs, those treated with PI had a 4.29 % higher total prescription drug cost on 
average, however, incremental cost was not statistically significant (p=0.4728). We also 
found that there was no statistically significant difference in changes to total prescription costs 
between: race, census region, hepatitis B/C (p=0.1251) or beneficiaries with dual eligibility 






Table 5.17 Adjusted GLM analysis of impact of T2DM on total prescription drug 
costs   
    Estimates  95 % CI P-Value 
Intercept 10.2656 9.8838 10.6474 <.0001 
T2DM     
 Negative (Ref)     
  Positive 0.0674 -0.0631 0.1978 0.3113 
Treatment with ART     
 Non-PIs (Ref)     
  PIs 0.0420 -0.0727 0.1567 0.4728 
Age Group     
 18 - 44 (Ref.)     
 45 - 54 0.0340 -0.1480 0.2161 0.7141 
 55 - 64 0.0950 -0.0827 0.2727 0.2947 
  65+ 0.1517 -0.2364 0.3330 0.5834 
Gender     
 Female (Ref)     
 Male 0.1075 -0.0206 0.2355 0.1000 
Race     
 Caucasian (Ref)     
 African America -0.0650 -0.1873 0.0572 0.2972 
  Other Race -0.0759 -0.2876 0.1358 0.4823 
Census Region     
 Midwest (Ref)     
 Northeast 0.0703 -0.1051 0.2458 0.4321 
 South -0.0398 -0.1960 0.1165 0.6178 
  West 0.1241 -0.0736 0.3219 0.2186 
Hepatitis C Virus     
 Negative (Ref)     
  Positive 0.1916 0.0510 0.3323 0.0076 
Charleson Comorbidity Index     
 0 (Ref)     
 1 0.8770 0.5654 1.1886 <.0001 
 2 1.1752 0.8610 1.4895 <.0001 
  3+ 1.2681 0.9512 1.5851 <.0001 
Dual Eligibility Status     
 No     
  Yes 0.0274 -0.0994 0.1541 0.6723 
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence  








5.3.5.5 Total Medicare cost 
 After controlling for potential confounders at the baseline in the GLM analysis 
(Table 5.18) the impact of T2DM on total Medicare cost was still statistically significantly 
higher among beneficiaries with comorbid T2DM compared to those without comorbid 
T2DM. Result show that compared to HIV/AIDS beneficiaries without comorbid T2DM, 
those with comorbid T2DM had 27.95 % [(e0.2465-1) *100] higher total Medicare costs on 
average (p=<.0001). 
Other covariates statistically significantly associated with changes in total Medicare 
cost include hepatitis B/C Virus and CCI characteristics. Compared to HIV/AIDS 
beneficiaries without hepatitis B/C virus comorbidity, those with hepatitis B/C virus 
comorbidity had 29.15 % higher total Medicare costs on average (p=<.0001). Compared to 
HIV/AIDS beneficiaries without any comorbidity (CCI=0), those with comorbidity of: CCI=1 
had 93.00 % higher total Medicare costs on average (p=<.0001), CCI=2 had 189.33 % higher 
total Medicare cost on average (p=<.0001), CCI=3+ had 309.68 % higher total Medicare cost 
on average (p=<.0001).  
Antiretroviral treatment with PIs did not significantly impact Medicare cost compare 
to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated with non-
PIs, those treated with PI had a 2.80 % higher total Medicare cost on average, however, 
incremental cost was not statistically significant (p=0.6036). Also, there was no statistically 
significant difference in changes to total Medicare cost between: age, race, region, male and 







Table 5.18 Adjusted GLM analysis of impact of T2DM on total Medicare 
costs  
    Estimates  95 % CI P-Value 
Intercept 10.4320 10.0895 10.7744 <.0001 
T2DM     
 Negative (Ref)     
  Positive 0.2465 0.1294 0.3636 <.0001 
Treatment with ART     
 Non-PIs (Ref)     
  PIs 0.0276 -0.0765 0.1316 0.6036 
Age Group     
 18 - 44 (Ref.)     
 45 - 54 0.0341 -0.1336 0.2018 0.6900 
 55 - 64 0.0786 -0.0848 0.2420 0.3456 
  65+ 0.0962 -0.0762 0.1638 0.9430 
Gender     
 Female (Ref)     
 Male 0.0393 -0.0772 0.1558 0.5089 
Race     
 Caucasian (Ref)     
 African America 0.0524 -0.0588 0.1636 0.3559 
  Other Race 0.0129 -0.1802 0.2060 0.8956 
Census Region     
 Midwest (Ref)     
 Northeast -0.0019 -0.1625 0.1587 0.9815 
 South -0.0809 -0.2243 0.0625 0.2691 
  West 0.1022 -0.0769 0.2813 0.2633 
Hepatitis C Virus     
 Negative (Ref)     
  Positive 0.2558 0.1290 0.3826 <.0001 
Charleson Comorbidity Index     
 0 (Ref)     
 1 0.6575 0.3831 0.9318 <.0001 
 2 1.0624 0.7859 1.3388 <.0001 
  3+ 1.4102 1.1332 1.6872 <.0001 
Dual Eligibility Status     
 No     
  Yes -0.0029 -0.1199 0.1141 0.9611 
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence  









5.3.5.6 Total medical cost 
 After controlling for potential confounders at the baseline in the GLM analysis 
(Table 5.19) the impact of comorbid T2DM on total medical costs was still statistically 
significantly higher among beneficiaries with comorbid T2DM compared to those without 
comorbid T2DM. Results show that compared to HIV/AIDS beneficiaries without comorbid 
of T2DM, those with comorbid T2DM had 27..82 % [(e0.2455-1) *100] higher total medical 
costs on average (p=<.0001). 
Other covariates statistically significantly associated with changes in total medical 
costs include hepatitis B/C Virus and CCI characteristics. Compared to HIV/AIDS 
beneficiaries without hepatitis B/C virus comorbidity, those with hepatitis B/C virus 
comorbidity had 27.21 % higher total medical costs on average (p=0.0001). Compared to 
HIV/AIDS beneficiaries without any comorbidity (CCI=0), those with a comorbidity of: 
CCI=1 had 92.97 % higher total medical costs on average (p=<.0001), CCI=2 had 185.68 % 
higher total medical costs on average (p=<.0001), CCI=3+ had 289.00 % higher total medical 
costs on average (p=<.0001).  
Antiretroviral treatment with PIs did not significantly impact total medical cost 
compare to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated 
with non-PIs, those treated with PI had a 2.93 % higher total medical cost on average, 
however, incremental cost was not statistically significant (p=0.5706). No statistically 
significant difference was found in the changes to total medical cost between male and female 
beneficiaries (p=0.3729), age category, race category, gender, region, and dual eligibility 






Table 5.19 Adjusted GLM analysis of impact of T2DM on total medical costs  
    Estimates  95 % CI P-Value 
Intercept 10.6445 10.3171 10.9718 <.0001 
T2DM     
 Negative (Ref)     
  Positive 0.2455 0.1334 0.3577 <.0001 
Treatment with ART     
 Non-PIs (Ref)     
  PIs 0.0289 -0.0710 0.1289 0.5706 
Age Group     
 18 - 44 (Ref.)     
 45 - 54 0.0078 -0.1532 0.1687 0.9246 
 55 - 64 0.0522 -0.1047 0.2090 0.5146 
  65+ 0.0758 -0.1691 0.2575 0.9444 
Gender     
 Female (Ref)     
 Male 0.0526 -0.0589 0.1642 0.3552 
Race     
 Caucasian (Ref)     
 African America 0.0661 -0.0406 0.1727 0.2248 
  Other Race -0.0014 -0.1862 0.1833 0.9877 
Census Region     
 Midwest (Ref)     
 Northeast -0.0175 -0.1721 0.1371 0.8244 
 South -0.1029 -0.2409 0.0351 0.1440 
  West 0.0727 -0.0995 0.2450 0.4077 
Hepatitis C Virus     
 Negative (Ref)     
  Positive 0.2407 0.1189 0.3625 0.0001 
Charleson Comorbidity Index     
 0 (Ref)     
 1 0.6574 0.3957 0.9191 <.0001 
 2 1.0497 0.7858 1.3137 <.0001 
  3+ 1.3584 1.0937 1.6230 <.0001 
Dual Eligibility Status     
 No     
  Yes 0.0078 -0.1041 0.1198 0.8912 
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence  








5. 4  Sensitivity Analysis 
The use of the PS matching approach in study aim 1 and 2 included only matched 
beneficiaries in the analytical sample and excluded unmatched beneficiaries, which may 
substantially impact the main results. To evaluate the sensitivity of these exclusions on the 
results, adjusted logistic regressions were re-fitted using the inverse probability-of-treatment 
weighting (IPTW) (instead of matching) which is a type of PS analytical method that uses 
complete samples in the analysis. This section presents the summary of the results of the 
sensitivity analysis of treatment with PI and the odds of developing T2DM, and the race sub-
group analysis of these effects. (Table 5.20). The results of sensitivity analysis are consisted 
with the main results based on PS matching approach in terms magnitude and direction of 
association.  
Compared to beneficiaries treated with non-PIs, those treated with PIs were shown to 
be 69% more likely to develop T2DM after adjusting for covariates (OR=1.69; 95% CI: 1.42-
2.01). (Table 5.20). Compared to beneficiaries who are not treated with ART, those treated 
with PIs were 73% more likely to develop T2DM after adjusting for covariates (OR=1.73; 
95% CI: 1.46-2.05).  
Considering race sub-group results, among Caucasian beneficiaries, it was found that 
compared to Caucasian beneficiaries treated with non-PI, those treated with PIs were 1.70 
times more likely to develop T2DM after adjusting for covariates (OR=1.70; 95% CI: 1.30-
2.22). Odds of developing T2DM among Caucasian beneficiaries who were treated with PI 
were 2.05 times higher than the odds of developing T2DM in Caucasian beneficiaries who 
were not treated with ART, after adjusting for covariates (OR=2.05; 95% CI: 1.52-2.77). We 
found that odds of developing T2DM among African American beneficiaries treated with PI 




treated with non-PI. (OR=2.17; 95% CI: 1.71 -2.76). Odds of developing T2DM among 
African American beneficiaries treated with PI were 2.20 times higher than the odds of 
developing T2DM in African American beneficiaries who were not treated with ART. 




















Table 5.20 Sensitivity analysis: Adjusted logistic regression analysis of factors 
associated with development of T2DM  
    AOR 95 % CI P-Value 
Medication Exposure     
 Non-PIs (Ref) 
  
  
  PIs 1.69 1.42 2.01 <.0001 
Medication Exposure     
 No-ART (Ref) 
  
  
  PIs 1.73 1.46 2.05 <.0001 
Caucasians Sub-groups     
Medication Exposure     
 Non-PIs (Ref) 
  
  
  PIs 1.70 1.30 2.22 0.0001 
Medication Exposure     
 No-ART (Ref) 
  
  
  PIs 2.05 1.52 2.77 <.0001 
African Americans Sub-groups         
Medication Exposure     
 Non-PIs (Ref) 
  
  
  PIs 2.17 1.71 2.76 <.0001 
Medication Exposure     
 No-ART (Ref) 
  
  
  PIs 2.20 1.74 2.79 <.0001 
PI: Protease Inhibitors, AOR: Adjusted Odds ratio, T2DM: Types II diabetes 






This chapter presents the discussion of all results in the context of existing 
evidence and presents the significance, innovation, strengths and limitations of this 
dissertation. 
6.1 Treatment with PI and Development of T2DM  
 One of the objectives of this dissertation is to assess the association between PIs 
use and incidences of T2DM comparing beneficiaries in both therapy group pairs- PIs 
versus non-PIs and PIs verse no-ART therapy groups. We compared PIs versus non-PIs 
therapy groups and found that among Medicare beneficiaries diagnosed with HIV/AIDS, 
beneficiaries treated with PIs had higher adjusted odds of developing T2DM compared to 
beneficiaries treated with non-PIs. Although this study reports evidence among the 
population of Medicare recipients, our results are similar to the findings in some previous 
studies which examined subjects sampled from other populations. Studies conducted by 
Capeau et al., in France analyzed medical records of a cohort of 1,046 patients followed 
over a 10-year period. Conclusions showed that short term exposure to indinavir was 
associated with increased incidences of T2DM 74, which is similar to the increased odds 
of developing T2DM found in this study. Similarly, Ledergerber et al followed 6,513 
HIV patients over a six year analytical period and found that the use of PIs based RTIs 




et al. and Hughes et al. demonstrated that use of PI was independently associated with 
elevated hyperglycemia and an increase in development of T2DM, respectively.102,103 A 
2-fold increase (two-fold (AOR: 1.52) in the odds of developing T2DM in Hughes et 
al.103  is similar to the two-fold (AOR: 1.74) increase found in this study.  
This study incorporated non-PIs groups as a control group (mainly the NNRTIs 
and NRTIs) when assessing association between T2DM and PIs use, which is similar to 
the control group used in Justman et al.104 Justman and his colleagues analyzed the risk of 
diabetes in a cohort of 1,785 non-pregnant HIV positive women treated with PIs versus 
those treated with RTIs.104 After a four-year follow-up, they found that patients treated 
with PIs had an increase in incidences of diabetes compare to RTI users, which is similar 
to the findings of this study.104  Our result is similar to findings from a previous study 
which incorporated a PI naïve group as a control group. Carr et al. compared PIs with PIs 
naïve HIV patients after 2-years of follow-up and found that hyperlipidemia and impaired 
glucose were significantly common among PI users compared to PI-naïve HIV 
patients.105 Given that subjects in the PI-naïve control group in Carr et al were exposed to 
other ARTs just as the non-PI control group in this study, our findings corroborates the 
findings of Carr et al. 
Although this study demonstrates an association of treatment with PIs and 
increased odds of developing T2DM within the Medicare population, our result is similar 
to Tripathi et al. which analyzed South Carolina Medicaid HIV/AIDS population. They 
found that cumulative exposure to protease inhibitors are significantly associated with a 
higher risk of diabetes among the South Carolina Medicaid population.108 Evidence from 




be extended to the national level. However, since similar evidence exists in the Medicare 
population as we found in this study, it could be hypothesized that the treatment with PI 
may be associated with an increased risk of developing diabetes within the national 
Medicaid HIV/AIDS population as well, just as the national Medicare population in this 
study. Future studies should focus on analyzing national Medicaid beneficiaries with 
HIV/AIDS in other to provide evidence on both national Medicare and Medicaid 
populations. This will help the CMS in developing a risk management approach for 
clinical management of HIV in both Medicaid and Medicare beneficiaries when using 
PIs. 
This study incorporated no-ARTs as a control group and directly compared PIs 
versus no-ART therapy groups. Results based on this therapy group pair shows the extent 
to which the odds of developing T2DM could vary between individuals treated with PIs 
versus those who were not treated with any ART, which, at best, provides a clear-cut 
estimate of association of PIs and T2DM. None of the published studies that reported 
association between PIs and increased incidences of T2DM incorporated or directly 
compared a no-ART group as a control group with a PIs group when estimating the risk 
of T2DM. In this study, we found that among Medicare beneficiaries diagnosed with 
HIV/AIDS, those treated with PIs had higher adjusted odds of developing T2DM 
compared to beneficiaries not treated with ARTs. In Justman et al, RTIs were 
incorporated as a control group for comparison pairs – RTI versus PI and RTI versus no-
ART comparison pairs.104 In RTIs versus no-ART, they found an increasing risk of 
T2DM among the RTI groups compared to no-ART, although the result was not 




PI compared to RTI groups. While RTI versus no-ART comparison is not similar to the 
PI versus no-ART used in this study, it could be carefully deduced from Justman et al 
that a PIs versus no-ART comparison may show in increasing risk of developing T2DM 
if it was compared in their study. 
This study analyzed the odds of developing T2DM between a PIs versus non-PIs 
group and PIs versus no-ARTs group and found increased odds of developing T2DM in 
PIs versus non-PIs (AOR: 1.74) and PI versus no-ART groups (AOR: 1.83), respectively. 
As expected, the odds of developing T2DM is higher in the no-ARTs comparison group 
than in the non-PIs comparison group. Given that previous studies had shown that the use 
of RTIs are association with an increased risk of developing T2DM 121-123,174, thus 
individuals in the PIs versus non-PIs comparison groups have T2DM risks higher than 
the baseline risk. Hence, comparing PIs versus non-PIs would results to a smaller odds 
ratio than in PI versus no-ART (the probability of T2DM in PI group/ divided by the 
probability of T2DM in non-PIs group). On the other hand, the T2DM risk in the no-ART 
arm are generally the baseline T2DM risk and much smaller than the risk of T2DM in the 
PIs arm, thus comparison of PIs versus no-ARTs will result to a larger odds ratio 
(probability of T2DM in PI group divided by the probability of T2DM in non-PIs group) 
than in PIs versus no-ARTs comparison.  
6.2  Race Sub-group Analysis of PI Use and Development of T2DM 
 This study is the first to report racial disparities in odds of developing T2DM 
among patients treated with PIs. We examined racial disparities in odds of developing 
T2DM comparing beneficiaries treated with PIs versus those treated with non-PIs, and 




In the PIs versus non-PIs comparison groups, we found that African American 
beneficiaries treated with PI had higher odds of developing T2DM compared to African 
American beneficiaries treated with non-PIs. We also found that Caucasian beneficiaries 
treated with PIs had higher odds of developing T2DM compared to Caucasian 
beneficiaries treated with non-PI. The odds of developing T2DM was higher in African 
American race-subgroup (OR=2.09) compare to the odds among Caucasian race-
subgroup (OR=1.90). This finding agrees with our hypothesis which states that in 
comparing PIs and non-PIs therapy group, the odds of developing T2DM after PIs use is 
higher among African American race compared to the odds of developing T2DM after 
PIs use among the Caucasian beneficiaries.   
In the PI versus no-ART comparison groups, we found that African American 
beneficiaries treated with PI had higher odds of developing T2DM compared to African 
American beneficiaries who were not treated with ARTs. We also found that Caucasian 
beneficiaries treated with PIs had higher odds of developing T2DM compared to 
Caucasian beneficiaries not treated with ART. Again, we found that the odds of 
developing T2DM was higher in African American race-subgroup (OR=2.39) compared 
to the odds among Caucasian race-subgroup (OR=1.86). These findings agree with our 
hypothesis which states that in comparing PIs and no-ARTs therapy group, the odds of 
developing T2DM after PIs use are higher among African American race compared to the 
odds of developing T2DM after PIs use among the Caucasian beneficiaries.   
In the analysis of each therapy group pairs, our study demonstrates that use of PIs 
is associated with higher odds of developing T2DM in both race subgroups. Specifically, 




and Caucasian Medicare beneficiaries with HIV/AIDS infection. However, we found that 
the impact was higher in one race sub-group than the other. This study reports that the 
odds of developing T2DM was higher in African Americans treated with PIs compared to 
Caucasians treated with PIs.  
Previous racial disparities studies had reported that African Americans have 
higher prevalence of T2DM compare to Caucasians. According to the CDC, African 
American and other racial and ethnic minority populations remain at higher risk for 
incident T2DM and its complications.175 However, recent studies by Bancks et al 
suggested that African Americans and Caucasians actually have the same biological risk 
of developing T2DM.176  They concluded that the there is no racial disparities in risk of 
developing T2DM after accounting for various modifiable risk factors such as family 
history of diabetes, racial segregation, tract-level poverty, depressive symptoms, family 
education, current employment, alcohol consumption, and smoking rather than genetic 
factors.176 The difference in odds of developing T2DM between African Americans and 
Caucasians in our study could result from some of the underlying factors which were not 
controlled for in this study. Factors such as family history of diabetes, depressive 
symptoms, education, employment and behavioral factors such as alcohol consumption 
and smoking.  
6.3  Economic Burden of Comorbid T2DM 
 This study is the first to evaluate the national economic burden of comorbid 
T2DM in HIV/AIDS. We found that compared to HIV/AIDS positive beneficiaries 
without comorbid T2DM, those with comorbid T2DM had higher total hospitalization 




higher total medical cost on average. Conversely, this study did not detect a significant 
difference in total cost of prescription drugs between beneficiaries with history of T2DM 
and those without. Except for total cost of prescription drugs, the findings of this study 
are similar to our hypothesis for all other health costs.  
This finding is in tandem with the study conducted by Zingmond et al which 
described the comorbidities in people living with HIV/AIDS in relation to hospitalization, 
inpatient and prescription drug costs.7 They reported that among California Medicare 
beneficiaries with HIV/AIDS, comorbidity is associated with increase in median inpatient 
costs and outpatient costs paid by the Medicare and patients.7 Given the clinical 
breakthrough in HIV/AIDS management since advent of ARTs which includes 
decreasing hospitalization rates and ambulatory care for HIV/AIDS patients, 
hospitalization is now largely due to non-HIV/AIDS comorbidities, infections and 
complications.177 Approximately 71 % of deaths among hospitalized HIV/AIDS patients 
is attributed to non-HIV related conditions such as other infections and various chronic 
diseases.177 In other words, comorbidities itself has a significant impact on mortality rate 
among hospitalized patients with HIV/AIDS as well as total hospitalization cost paid by 
patients and their insurance providers. Thus, the total hospitalization costs, outpatient 
costs, OOP costs, total Medicare costs and total medical costs is expected to be sensitive 
to comorbid T2DM as found in this study.  
In contrast to the sensitivity of these costs to comorbid T2DM, we found that 
prescription drug cost is insensitive to comorbid T2DM. Prescription drug cost is not 
sensitive to comorbid T2DM  because the high cost of ARTs outweighs the cost of anti-




difference in terms of total prescription drug costs for HIV/AIDS patients. This finding is 
in tandem with the study conducted by Zingmond et al which found that ARTs constitute 
the largest share of cost of care for HIV patients and suggested that because ARTs are 
more expensive than medication for other comorbidities, comorbidities would have no 
significant impact on cost of prescription for patients with HIV/AIDS which outweighs 
medication costs for other conditions. 7 
6.4  Sensitivity Analysis 
 We performed a sensitivity analysis using IPTW approach to evaluate the 
sensitivity of excluding unmatched beneficiaries on the results of study aim 1 and 2 using 
adjusted logistic regressions. We found that the sensitivity analysis results were similar to 
the main result in aim 1 and 2 in terms of between group associations and direction of 
associations. Analysis of the PS matched sample in this study is not sensitive to the 
exclusion of unmatched samples.  
6.5  Innovation 
This study is innovative in the following three important areas. To begin with, it is 
the first study of its kind to examine the odds of developing T2DM following PIs use 
among Medicare beneficiaries diagnosed with HIV/AIDS. Second, the most recent 
Medicare data (2012-2017) was used for this study enabling the evaluation of the odds of 
T2DM using current and recent FDA approved ARTs and generate the most current 
evidence. No previous studies in the current literature have examined this topic. Third, 
this study is the first to determine racial disparity in the odds of developing T2DM 




have examined the race/ethnicity disparity in the odds of developing T2DM among 
Medicare beneficiaries with HIV in current literature. Fourth, this study is the first of its 
kind to explore the economic burden of comorbid T2DM among the HIV/AIDS positive 
Medicare population. The evidence generated by this study is the first and the most 
current national economic burden with estimates that are adjusted to the 2017 dollar. No 
previous studies have examined the national economic burden of comorbid T2DM. 
6.6  Limitations  
Several data and study design related limitations may exist in this study. This 
study is a non-randomized observational study. Although we used PS matching approach 
to account for potential selection bias due to non-randomization into therapy groups. 
However, only the beneficiary characteristics available in the Medicare data were used 
for the PS matching. Also, as a limitation of the PS matching approach, it is unable to 
account for unmeasured confounders that could have impacted the results of this study. 
The study aim 3 used cross-sectional study design to analyze economic burden of T2DM 
on health care costs however, this study design could not establish causality of 
association. Thus, the change in healthcare cost between beneficiaries with T2DM and 
those without cannot be causally attributed to T2DM in this study.  
Some data related limitations have been noted. Several potential confounders 
were not observed in this study and thus were not controlled for. Medicare data has 
limited information on risk factors of diabetes including physical activities of the 
beneficiaries, a family history of diabetes, diets and other lifestyle behaviors. The 
Medicare database does not have vital HIV related clinical information such as CD4 




determinant of the type ART prescribed. As a secondary data which is originally 
collected for administrative and billing purposes rather than for this study, and of which 
data collection were not under the control of the investigators of this study, we suspect a 






This study found that use of PIs in HIV/AIDS positive Medicare beneficiaries 
may be associated with higher odds of developing T2DM than those who were managed 
with non-PIs and higher than those who were not treated with ARTs. These findings are 
consistent within both African American and Caucasian race sub-groups. However, 
African American race-subgroup had higher odds of developing T2DM in both PI versus 
no-ART and PI-versus non-PI comparison pairs than the odds among the Caucasian race-
subgroup. Furthermore, this study found that HIV/AIDS Medicare beneficiaries with a 
history of T2DM have higher total hospitalization costs, total outpatient costs, total OOP 
costs, total Medicare costs and total medical costs than HIV/AIDS positive beneficiaries 
without a history of T2DM 
This study presents three policy impacting significances. First, in the light of the 
controversies regarding safety and tolerability of PIs, a clinical risk management 
approach is a necessity when treating the elderly and the Medicare beneficiaries who 
have HIV/AIDS. This becomes important because treatment of HIV infection and 
consequently creating or exacerbating the onset of another condition, such as T2DM, is a 
huge concern to clinicians, the Medicare system, and patients. As a preventable adverse 
event, the findings of this study will guide clinicians and infectious disease experts in 




the clinical use of PIs among the Medicare population with HIV/AIDS. Evidence-based 
risk management approach will help avoid HIV treatment related T2DM in this 
population, who are already enormously predisposed. 
Second, racial/ethnic variations in HIV/AIDS epidemiology and treatment has 
been established. As a vulnerable population with less HIV-care and attention, evidence 
of racial/ethnic disparity in the odds of developing T2DM following PIs use is key in 
ensuring proper risk management across race sub-groups. The findings of our study 
suggest that while the odds of developing T2DM is consistent in both African American 
and Caucasian race sub-groups, the odds were higher in African Americans than in 
Caucasians. Our study suggests that personalized medicine should be considered when 
planning clinical risk management approach for use of PIs with a consideration for the 
race-subgroup in whom risks of T2DM are higher. 
The increasing population of Medicare beneficiaries with HIV, who are at higher 
risk for T2DM, suggests an increasing population of HIV positive beneficiaries with 
comorbid T2DM. This may pose a significant economic burden on the Medicare system, 
which is already the largest source of Federal spending for HIV care. As the population 
ages and life expectancies increase, Medicare plans to continue to play an increasingly 
significant role in HIV care, which is why it is important to understand the economic 
burden of comorbid T2DM. Given the growing aging population and increasing per 
capita costs for HIV positive beneficiaries, evidence of the national economic burden of 
comorbid T2DM among Medicare beneficiaries with HIV/AIDS would be important to 
Medicare policy makers as they consider options and ways to address concerns about 




evidence on specific cost domains which are specific for evaluating and generating 
policies that target a specific aspect of health care use and cost domains. For instance, 
evidence of total OOP costs and total prescription drug costs would benefit Medicare 
policy makers as they draft proposals to reduce drug costs, which could be beneficial to 
HIV positive beneficiaries facing high OOP expenses.  
In summary, the significance of this study cannot be over emphasized. It 
addresses issues that impact both the Medicare system and the patients and their racial 
identification. The odds of developing T2DM after PIs use and the economic burden of 
comorbid T2DM provides critical empirical evidence for policy considerations that 
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